Reversible lysine covalent modifiers of cdk2 and uses thereof

Abstract

In some aspects, this disclosure provides compounds of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof, for regulating CDK2. In other aspects, this disclosure provides methods for treating CDK2-mediated diseases or conditions such as oncology indications using compounds of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof. (I)

Description

[0001] Cross-referencing This application claims the benefit of U.S. Provisional Application No. 63 / 545,413, filed October 24, 2023, and U.S. Provisional Application No. 63 / 674,639, filed July 23, 2024, the entire contents of each of which are incorporated herein by reference. Background of the Invention Cyclin-dependent kinases (CDKs) belong to the serine / threonine kinase family and are involved in cell cycle progression and cell division. Dysregulation of CDK activity is associated with abnormal cell cycle regulation and has been detected in almost all types of human cancer (Sherr, CJ). Science , 1996, 274 (5293), 1672-1677). Activation of CDK requires the formation of heterodimers with other regulatory subunits, these dimers being called cyclins. Among them, cyclin E (CDK2 regulator) is often overexpressed in cancer. Its amplification or overexpression has long been associated with poor prognosis in breast cancer, inflammatory breast cancer, and trastuzumab resistance in HER2+ breast cancer (Keyomarsi, K et al., 1996, 274 (5293), 1672-1677). N Engl J Med ., 2002, 347, 1566-1575; Scaltriti, M et al., Proc Natl Acad Sci 2011, 108, 3761-3766; Alexander, A. et al. Oncotarget 2017, 8, 14897-14911). Furthermore, cyclin E1 amplification or overexpression is also associated with poor prognosis in ovarian cancer, gastric cancer, endometrial cancer, and other cancers (Nakayama, N et al., 2017, 8, 14897-14911). Cancer 2010, 116, 2621-2634; Etemadmoghadam, D et al. Clin Cancer Res (2013, 19, 5960-5971). However, due to the similarity of CDK2 to other CDKs, the development of selective CDK2 inhibitors has been challenging. To date, no drugs selectively targeting CDK2 have been approved. Therefore, there is an urgent need to develop new selective CDK2 modulators for oncology. Summary of the Invention

[0003] In one respect, this disclosure provides compounds represented by the structure of formula (I): (I); Or its pharmaceutically acceptable salt, wherein: Ring A is selected from C 3-12 Carbon rings and 3- to 12-membered heterocycles; R 5 Selected from the electrophilic portion or its prodrug; Each R 4 Selected independently each time it appears: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i) Hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; (ii) C 1-6 Alkyl, C 2-6 alkenyl and C2-6 Each of the ynyl groups is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: Halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R15 ) and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 Carbocyclic rings and 3- to 6-membered heterocycles, optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

[0004] In some embodiments, the electrophilic moiety or its prodrug is a lysine-reactive electrophile. In some embodiments, the lysine-reactive electrophile is selected from reversible and irreversible lysine-reactive electrophiles. In some embodiments, the electrophilic moiety is selected from haloacetamides, haloalkyl ketones, haloamidines, halobenzylphosphonates, acyloxyalkyl ketones, sulfonyl ethylene oxides, epoxides, diazonyl ketones, halotriazines, acrylamides, cyanoacrylamides, vinyl sulfones, vinyl sulfonamides, acrylates, aldehydes, borate esters, halosulfonyl groups, esters, squaric acid esters, squaric acid esters, fumarate esters, carbonyl acrylates, maleimides, ketoamides, nitriles, alkenes, alkynes, ketone heterocycles, and acetylides. In some embodiments, the electrophilic moiety or its prodrug is an aldehyde or its prodrug. In some embodiments, the electrophilic moiety or its prodrug is an imine. In some embodiments, the electrophilic moiety or its prodrug is an aldehyde.

[0005] On the other hand, compounds or salts of formula (I) are represented by the structures of formula (II): (II), or a pharmaceutically acceptable salt thereof.

[0006] On the other hand, compounds or salts of formula (I) are represented by the structures of formula (III): (III), or a pharmaceutically acceptable salt thereof.

[0007] In one aspect, this disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutically acceptable salt thereof.

[0008] In another aspect, this disclosure provides a method for regulating CDK2, comprising administering to a subject in need a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutical composition thereof.

[0009] In another aspect, this disclosure provides a method for inhibiting CDK2, comprising administering to a subject in need a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutical composition thereof.

[0010] In another aspect, this disclosure provides a method for treating a CDK2-mediated disease or condition, comprising administering to a subject in need a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutical composition thereof.

[0011] In another aspect, this disclosure provides a method of treating cancer, comprising administering to a subject in need a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutical composition thereof.

[0012] In another aspect, this disclosure provides a method for inhibiting cell proliferation, comprising administering to a subject in need a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) or a pharmaceutical composition thereof.

[0013] Incorporation All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference to the extent that each individual publication, patent, or patent application is expressly and individually indicated to be incorporated by reference. If any incorporated publication, patent, or patent application contradicts the disclosure contained in this specification, this specification is intended to supersede and / or take precedence over any such contradictory material. Attached Figure Description

[0014] The novel features of this invention are specifically set forth in these claims. The features and advantages of this invention can be better understood by referring to the following detailed description of exemplary embodiments (in which the principles of the invention are applied) and the accompanying drawings, wherein: Figure 1A-1P Complete proteomic spectra of pCDK2-CCNE1 incubated with the compound of this disclosure under conditions of no competing molecules and in the presence of a significantly stoichiometric excess of a competing molecule (PF-06873600) are provided. Figure 1A-1B Complete proteomic spectra of pCDK2-CCNE1 and compound 11 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1C-1D Complete proteomic spectra of pCDK2-CCNE1 and compound 13 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1E-1F Complete proteomic spectra of pCDK2-CCNE1 and compound 17 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1G-1H Complete proteomic spectra of pCDK2-CCNE1 and compound 17 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1I-1J Complete proteomic spectra of pCDK2-CCNE1 and compound 22 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1K-1LComplete proteomic spectra of pCDK2-CCNE1 and compound 51 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1M-1N Complete proteomic spectra of pCDK2-CCNE1 and compound 69 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600. Figure 1O-1P Complete proteomic spectra of pCDK2-CCNE1 and compound 32 were provided under conditions of no competing molecules and in the presence of a significant stoichiometric excess of the competing molecule PF-06873600.

[0015] Figure 2A-2N The complete protein spectrum of pCDK2-CCNE1 protein after incubation with the compounds disclosed herein and subsequent reduction with sodium borohydride is provided. Figure 2A A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 11 is provided. Figure 2B A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 13 is provided. Figure 2C A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 17 is provided. Figure 2D A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 22 is provided. Figure 2E A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 16 is provided. Figure 2F A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 51 is provided. Figure 2G A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 64 is provided. Figure 2H A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 69 is provided. Figure 2I A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 45 is provided. Figure 2J A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 32 is provided. Figure 2K A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 49 is provided. Figure 2L A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 82 is provided. Figure 2M A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 89 is provided. Figure 2N A complete proteomic spectrum of pCDK2-CCNE1 incubated with compound 103 is provided.

[0016] Figure 3A-3NDissociation rate data for pCDK2-CCNE1 treated with compounds of this disclosure in competition with excess PF-06873600 are provided. Figure 3A The dissociation rate study of compound 11 with pCDK2-CCNE1 is shown. Figure 3B The dissociation rate study of compound 13 with pCDK2-CCNE1 is shown. Figure 3C The dissociation rate study of compound 17 with pCDK2-CCNE1 is shown. Figure 3D The dissociation rate study of compound 22 with pCDK2-CCNE1 is shown. Figure 3E The dissociation rate study of compound 16 with pCDK2-CCNE1 is shown. Figure 3F The dissociation rate study of compound 51 with pCDK2-CCNE1 is shown. Figure 3G The dissociation rate study of compound 64 with pCDK2-CCNE1 is shown. Figure 3H The dissociation rate study of compound 69 with pCDK2-CCNE1 is shown. Figure 3I The dissociation rate of compound 45 with pCDK2-CCNE1 is shown. Figure 3J The dissociation rate study of compound 32 with pCDK2-CCNE1 is shown. Figure 3K The dissociation rate study of compound 49 with pCDK2-CCNE1 is shown. Figure 3L The dissociation rate study of compound 82 with pCDK2-CCNE1 is shown. Figure 3M The dissociation rate study of compound 89 with pCDK2-CCNE1 is shown. Figure 3N The dissociation rate study of compound 103 with pCDK2-CCNE1 is shown.

[0017] Figure 4A-4C A schematic diagram of the eutectic structure of the pCDK2-CCNE1 complex and compound 13 is provided. Figure 4A A two-dimensional schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 13 is provided, wherein pCDK2-CCNE1 is shown in a cartoon model and compound 13 and CDK2 lysine residue K89 are shown in a stick model. Figure 4B A two-dimensional magnified schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 13 is provided, wherein compound 13 is depicted in a coarser rod model and the pCDK2-CCNE1 residues are depicted in a finer rod model. Figure 4C A two-dimensional magnified schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 13 is provided, which shows in detail the interaction between CDK2 residues and compound 13, specifically the imine bond between the K89 lysine residue of CDK2 and compound 13.

[0018] Figure 5A-5C A schematic diagram of the eutectic structure of the pCDK2-CCNE1 complex and compound 17 is provided. Figure 5A A two-dimensional schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 17 is provided, wherein pCDK2-CCNE1 is shown in a cartoon model and compound 17 and CDK2 lysine residue K89 are shown in a stick model. Figure 5B A two-dimensional magnified schematic diagram of the eutectic structure of the pCDK2-CCNE1 complex and compound 17 is provided, wherein compound 17 is depicted in a coarser rod model and the pCDK2-CCNE1 residues are depicted in a finer rod model. Figure 5C A two-dimensional magnified schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 17 is provided, which shows in detail the interaction between CDK2 residues and compound 17, specifically the imine bond between the K89 lysine residue of CDK2 and compound 17.

[0019] Figure 6A-6C A schematic diagram of the eutectic structure of the pCDK2-CCNE1 complex and compound 64 is provided. Figure 6A A two-dimensional schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 64 is provided, in which pCDK2-CCNE1 is shown in a cartoon model and compound 64 and CDK2 lysine residue K89 are shown in a stick model. Figure 6B A two-dimensional magnified schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 64 is provided, wherein compound 64 is depicted in a coarser rod model and the pCDK2-CCNE1 residues are depicted in a finer rod model. Figure 6C A two-dimensional magnified schematic diagram of the co-crystal structure of the pCDK2-CCNE1 complex and compound 64 is provided, which shows in detail the interaction between CDK2 residues and compound 64, specifically the imine bond between the K89 lysine residue of CDK2 and compound 64.

[0020] Figure 7A-7B The plasma concentrations of compounds 64 and 64a in mice after oral and IV administration were provided. Figure 7A The plasma concentrations of compounds 64 and 64a were shown after oral administration to mice. Figure 7B This shows the plasma concentrations of compounds 64 and 64a after intravenous administration to mice. Detailed Implementation

[0021] While preferred embodiments of the invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, modifications, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein can be used to practice the invention. The scope of the invention is intended to be defined by the following claims, and covers the methods and structures within the scope of these claims and their equivalents.

[0022] definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. All patents and publications mentioned herein are incorporated herein by reference.

[0023] As used in the specification and claims, unless the context clearly indicates otherwise, the singular forms “a”, “an” and “the” include plural references.

[0024] "Alkyl" refers to a compound consisting only of carbon and hydrogen atoms, without any unsaturation, and preferably having one to twelve carbon atoms (i.e., C1-C1). 12 An alkyl group is a straight-chain or branched hydrocarbon chain monovalent group. The alkyl group is attached to the rest of the molecule by a single bond. In some embodiments, the alkyl group contains one to twelve carbon atoms (i.e., C1-C1). 12 Alkyl group. In some embodiments, the alkyl group comprises one to eight carbon atoms (i.e., C1-C8 alkyl). In other embodiments, the alkyl group comprises one to five carbon atoms (i.e., C1-C5 alkyl). In other embodiments, the alkyl group comprises one to four carbon atoms (i.e., C1-C4 alkyl). In other embodiments, the alkyl group comprises one to three carbon atoms (i.e., C1-C3 alkyl). In other embodiments, the alkyl group comprises one to two carbon atoms (i.e., C1-C2 alkyl). In other embodiments, the alkyl group comprises one carbon atom (i.e., C1 alkyl). In other embodiments, the alkyl group comprises five to fifteen carbon atoms (i.e., C5-C6 alkyl). 15 Alkyl group). In other embodiments, the alkyl group comprises five to eight carbon atoms (i.e., C5-C8 alkyl). In other embodiments, the alkyl group comprises two to five carbon atoms (i.e., C2-C5 alkyl). In other embodiments, the alkyl group comprises three to five carbon atoms (i.e., C3-C5 alkyl). For example, the alkyl group can be attached to the rest of the molecule by a single bond, such as methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl), etc.

[0025] "Alkenyl" refers to a compound consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and preferably having two to twelve carbon atoms (i.e., C2-C). 12 An alkenyl group is a straight-chain or branched hydrocarbon chain group. In some embodiments, the alkenyl group comprises two to eight carbon atoms (i.e., C2-C8 alkenyl). In some embodiments, the alkenyl group comprises two to six carbon atoms (i.e., C2-C6 alkenyl). In other embodiments, the alkenyl group comprises two to four carbon atoms (i.e., C2-C4 alkenyl). The alkenyl group is connected to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), propenyl (i.e., allyl), butenyl, pentenyl, pent-1,4-dienyl, etc.

[0026] "Alkyne" refers to a group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, and preferably having two to twelve carbon atoms (i.e., C2-C). 12 An alkynyl group is a straight-chain or branched hydrocarbon chain group. In some embodiments, the alkynyl group comprises two to eight carbon atoms (i.e., C2-C8 alkynyl). In other embodiments, the alkynyl group comprises two to six carbon atoms (i.e., C2-C6 alkynyl). In still other embodiments, the alkynyl group comprises two to four carbon atoms (i.e., C2-C4 alkynyl). The alkynyl group is linked to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentyynyl, hexynyl, etc.

[0027] "Alkylene" refers to a straight-chain divalent hydrocarbon chain consisting only of carbon and hydrogen, without any degree of unsaturation, and preferably having one to twelve carbon atoms, with the remainder of the molecule connected to a group. Examples include methylene, ethylene, propylene, butylene, etc. The alkylene chain is connected to the remainder of the molecule by single bonds and to the group by single bonds. The connection points between the alkylene chain and the remainder of the molecule, and with the group, are located at the terminal carbons. The alkylene chain may optionally be substituted with one or more substituents (such as those described herein). In some embodiments, the alkylene comprises one to ten carbon atoms (i.e., C1-C1). 10Alkylenes. In some embodiments, the alkylene comprises one to eight carbon atoms (i.e., C1-C8 alkylene). In other embodiments, the alkylene comprises one to five carbon atoms (i.e., C1-C5 alkylene). In other embodiments, the alkylene comprises one to four carbon atoms (i.e., C1-C4 alkylene). In other embodiments, the alkylene comprises one to three carbon atoms (i.e., C1-C3 alkylene). In other embodiments, the alkylene comprises one to two carbon atoms (i.e., C1-C2 alkylene). In other embodiments, the alkylene comprises one carbon atom (i.e., C1 alkylene). In other embodiments, the alkylene comprises five to eight carbon atoms (i.e., C5-C8 alkylene). In other embodiments, the alkylene comprises two to five carbon atoms (i.e., C2-C5 alkylene). In other embodiments, the alkylene comprises three to five carbon atoms (i.e., C3-C5 alkylene).

[0028] "Alkenyl" refers to a straight-chain divalent hydrocarbon chain consisting only of carbon and hydrogen, containing at least one carbon-carbon double bond, and preferably having two to twelve carbon atoms, with the remainder of the molecule connected to a group. The alkenyl chain is connected to the remainder of the molecule by single bonds and to the group by single bonds. The connection points of the alkenyl chain to the remainder of the molecule and to the group are located at the terminal carbons. The alkenyl chain may optionally be substituted with one or more substituents (such as those described herein). In some embodiments, the alkenyl group contains two to ten carbon atoms (i.e., C2-C). 10 (Alkenyl group). In some embodiments, the alkenyl group comprises two to eight carbon atoms (i.e., C2-C8 alkenyl). In other embodiments, the alkenyl group comprises two to five carbon atoms (i.e., C2-C5 alkenyl). In other embodiments, the alkenyl group comprises two to four carbon atoms (i.e., C2-C4 alkenyl). In other embodiments, the alkenyl group comprises two to three carbon atoms (i.e., C2-C3 alkenyl). In other embodiments, the alkenyl group comprises two carbon atoms (i.e., C2 alkenyl). In other embodiments, the alkenyl group comprises five to eight carbon atoms (i.e., C5-C8 alkenyl). In other embodiments, the alkenyl group comprises three to five carbon atoms (i.e., C3-C5 alkenyl).

[0029] "Imyynyl" refers to a straight-chain divalent hydrocarbon chain consisting only of carbon and hydrogen, containing at least one carbon-carbon triple bond, and preferably having two to twelve carbon atoms, with the remainder of the molecule connected to a group. The ynylyl chain is connected to the remainder of the molecule and to the group via single bonds. The connection points of the ynylyl chain to the remainder of the molecule and to the group are located at the terminal carbons. The ynylyl chain may optionally be substituted with one or more substituents (such as those described herein). In some embodiments, the ynylyl group contains two to ten carbon atoms (i.e., C2-C). 10The ynyl group (C2-C8 ynyl group) comprises two to eight carbon atoms in some embodiments. In other embodiments, the ynyl group comprises two to five carbon atoms (C2-C5 ynyl group). In other embodiments, the ynyl group comprises two to four carbon atoms (C2-C4 ynyl group). In other embodiments, the ynyl group comprises two to three carbon atoms (C2-C3 ynyl group). In other embodiments, the ynyl group comprises two carbon atoms (C2 ynyl group). In other embodiments, the ynyl group comprises five to eight carbon atoms (C5-C8 ynyl group). In other embodiments, the ynyl group comprises three to five carbon atoms (C3-C5 ynyl group).

[0030] Term "C" x-y When used in conjunction with chemical moieties such as alkyl, alkenyl, or ynyl, it means to include groups containing x to y carbons in the chain. For example, the term "C 1-6 "Alkyl" refers to a substituted or unsubstituted saturated hydrocarbon group containing 1 to 6 carbons, including straight-chain alkyl and branched-chain alkyl groups. Term -C x-y Alkylene refers to a substituted or unsubstituted alkylene chain having x to y carbons. For example, -C 1-6 The alkylene group can be selected from methylene, ethylene, propylene, butylene, pentylene, and hexylene, any one of which may be substituted.

[0031] Term "C" x-y "Alkenyl" and "C" x-y "Alkyne" refers to an unsaturated aliphatic group with a similar length and possible substitution to the alkyl groups described above, but containing at least one double or triple bond. Term -C x-y Idemenyl refers to an substituted or unsubstituted alkyl chain having x to y carbons. For example, -C 2-6 The alkenyl group is selected from vinylene, propenylene, butenylene, pentenylene, and hexenylene, any one of which may be optionally substituted. The alkenyl chain may have one or more double bonds. Terminology - C x-y Alynyl group – refers to an alkynyl chain with x to y carbons, whether substituted or unsubstituted. For example, -C 2-6 The ynyl group can be selected from ethynyl, propynyl, butynyl, pentyynyl, and hexynyl, any one of which may be optionally substituted. The ynyl chain has one or more triple bonds.

[0032] As used herein, the term "carbocyclic ring" refers to a saturated, unsaturated, or aromatic ring in which each atom in the ring is carbon. Carbocyclic rings include 3- to 10-membered monocyclic rings and 6- to 12-membered bicyclic rings. Each ring in a bicyclic carbocyclic ring may be selected from saturated, unsaturated, and aromatic rings. Bicyclic carbocyclic rings may be fused, bridged, or spirocyclic systems. In some embodiments, the bicyclic carbocyclic ring is selected from fused, bridged, and spirocyclic carbocyclic rings. In some embodiments, the carbocyclic ring is aryl. In some embodiments, the carbocyclic ring is cycloalkyl. In some embodiments, the carbocyclic ring is cycloalkenyl. In exemplary embodiments, an aromatic ring (e.g., phenyl) may be fused to a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. Any combination of saturated, unsaturated, and aromatic bicyclic rings is included in the definition of a carbocyclic ring where the valence allows. Exemplary carbocyclic rings include cyclopentyl, cyclohexyl, cyclohexenyl, adamantyl, phenyl, dihydroindenyl, and naphthyl. The carbon ring can be optionally substituted by one or more substituents (such as those described herein).

[0033] As used herein, the term "carbocyclic group" refers to a divalent saturated, unsaturated, or aromatic ring, wherein each atom in the ring is carbon. The carbocyclic group is connected to the remainder of the molecule by a single bond and to a group by a single bond. The carbocyclic group may optionally be substituted with one or more substituents (such as those described herein). Carbocyclic groups include divalent 3- to 10-membered monocyclic rings and divalent polycyclic rings (e.g., 6- to 12-membered bicyclic rings). Each ring in a polycyclic carbocyclic group may be a self-saturated, unsaturated, or aromatic ring. Polycyclic carbocyclic groups can be fused, bridged, or spirocyclic systems. The single bond connecting the carbocyclic group to the remainder of the molecule and the single bond connecting the carbocyclic group to the group may be located on two different carbon atoms of the carbocyclic group. The single bond connecting the carbocyclic group to the remainder of the molecule and the single bond connecting the carbocyclic group to the group may be located on the same carbon atom of the carbocyclic group. The single bonds connecting the carbocyclic group to the rest of the molecule and the single bonds connecting the carbocyclic group to the functional group can be located on the same or different rings of the polycyclic carbocyclic group. In some embodiments, the carbocyclic ring is an arylene, such as a phenylene group. As used herein, "phenylene" refers to a divalent phenyl group. The phenylene group is connected to the rest of the molecule by a single bond and to a functional group by a single bond. The phenylene group may optionally be substituted with one or more substituents (such as those described herein).

[0034] "Cycloalkyl" refers to a stable, fully saturated monocyclic or polycyclic hydrocarbon group consisting only of carbon and hydrogen atoms, including fused or bridged systems, and preferably having three to twelve carbon atoms (i.e., C64-C ... 3-12 Cycloalkyl groups. In some embodiments, cycloalkyl groups contain three to ten carbon atoms (i.e., C646). 3-10 (Cycloalkyl). In other embodiments, the cycloalkyl group contains five to seven carbon atoms (i.e., C64-C72-C64 ... 5-7Cycloalkyl groups. A cycloalkyl group can be attached to the rest of the molecule via a single bond. Examples of monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl (i.e., bicyclic [2.2.1]heptyl), norbornenyl, decahydronaphthyl, 7,7-dimethyl-bicyclic [2.2.1]heptyl, etc. A cycloalkyl group may optionally be substituted with one or more substituents (such as those described herein).

[0035] "Cycloalkenyl" refers to a stable, unsaturated, non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon and hydrogen atoms, including fused or bridged ring systems, preferably having three to twelve carbon atoms and containing at least one double bond (i.e., C2H2O). 3-12 Cycloalkenyl group. In some embodiments, the cycloalkenyl group comprises three to ten carbon atoms (i.e., C64-C ... 3-10 Cycloalkenyl group. In other embodiments, the cycloalkenyl group comprises five to seven carbon atoms (i.e., C64-C ... 5-7 Cycloalkenyl groups can be attached to the rest of the molecule via a single bond. Examples of monocyclic cycloalkenyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. The cycloalkenyl group may optionally be substituted with one or more substituents (such as those described herein).

[0036] "Aryl" refers to a group derived from aromatic monocyclic or polycyclic aromatic hydrocarbon ring systems by removing hydrogen atoms from the ring carbon atoms. Aromatic monocyclic or polycyclic aromatic hydrocarbon ring systems contain only hydrogen and carbon, and five to eighteen carbon atoms, wherein at least one ring in the ring system is aromatic, that is, according to Hückel's theory, it contains cyclic, delocalized (4n+2) rings. Electronic systems. The cyclic systems of derived aryl groups include, but are not limited to, groups such as benzene, fluorene, indene, indene, tetrahydronaphthalene, and naphthalene. The aryl group may optionally be substituted with one or more substituents (such as those described herein).

[0037] “C x-y "Carbon ring" refers to a group containing x to y carbon atoms in the ring. For example, the term "C" 3-6 The "carbon ring" can be a saturated, unsaturated, or aromatic ring system containing 3 to 6 carbon atoms (any one of which may be substituted as provided herein).

[0038] As used herein, the term "heterocycle" refers to a saturated, unsaturated, non-aromatic, or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. Heterocycles include 3- to 10-membered monocyclic rings and 6- to 12-membered bicyclic rings. Each ring in a bicyclic heterocycle may be selected from saturated, unsaturated, and aromatic rings. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocycle contains at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocycle may be attached to the remainder of the molecule by any atom of the heterocycle, such as a carbon or nitrogen atom of the heterocycle, provided that the valence allows. In some embodiments, the heterocycle is a heteroaryl group. In some embodiments, the heterocycle is a heterocyclic alkyl group. Exemplary heterocycles include pyrrolidinyl, pyrrolithyl, imidazolyl, pyrazolyl, triazolyl, piperidinyl, pyridinyl, pyrimidinyl, pyridazinyl, thiophenyl, oxazolyl, thiazolyl, morpholinyl, indazole, indolyl, and quinolinyl. The heterocycle may optionally be substituted with one or more substituents (such as those described herein). Bicyclic heterocycles may be fused, bridged, or spirocyclic systems. In one exemplary embodiment, the heterocycle (e.g., pyridinyl) may be fused to a saturated or unsaturated ring, such as cyclohexane, cyclopentane, or cyclohexene. The heterocycle may optionally be substituted with one or more substituents (such as those described herein).

[0039] As used herein, the term "hypoheterocyclic group" refers to a divalent saturated, unsaturated, non-aromatic, or aromatic ring containing one or more heteroatoms. Exemplary heteroatoms include N, O, Si, P, B, and S atoms. The hypoheterocyclic group is connected to the remainder of the molecule by a single bond and to a group by a single bond. The single bonds connecting the hypoheterocyclic group to the remainder of the molecule and the single bonds connecting the hypoheterocyclic group to the group can be independently connected by any atom of the hypoheterocyclic group, including carbon atoms or heteroatoms in the hypoheterocyclic ring, as valence allows. The hypoheterocyclic group may optionally be substituted with one or more substituents (such as those described herein). Hypoheterocyclic groups include 3- to 10-membered monocyclic and polycyclic (e.g., 6- to 12-membered bicyclic) rings. Each ring in a polycyclic hypoheterocyclic group may be a self-saturated, unsaturated, or aromatic ring. Polycyclic hypoheterocyclic groups can be fused, bridged, or spirocyclic systems. The single bonds connecting the heterocyclic group to the remainder of the molecule and the single bonds connecting the heterocyclic group to the group may be located on two different carbon atoms of the heterocyclic group. Alternatively, the single bonds connecting the heterocyclic group to the remainder of the molecule and the single bonds connecting the heterocyclic group to the group may be located on the same carbon atom of the heterocyclic group. The single bonds connecting the heterocyclic group to the remainder of the molecule and the single bonds connecting the heterocyclic group to the group may be located on the same or different rings of the polycyclic heterocyclic group, and may be connected to the remainder of the molecule or the group via any atom of the heterocyclic group (such as a carbon or nitrogen atom of the heterocycle), subject to valence. In some embodiments, the heterocyclic group contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocyclic group contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocyclic group contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocyclic group is a heteroaryl group. In some embodiments, the heterocyclic group is a heterocyclic alkyl group.

[0040] "Heterocyclic alkyl" refers to a stable 3- to 12-membered non-aromatic cyclic group comprising two to twelve carbon atoms and at least one heteroatom, wherein each heteroatom may be selected from N, O, Si, P, B, and S atoms. In some embodiments, the heterocyclic alkyl contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heterocyclic alkyl contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heterocyclic alkyl contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. In some embodiments, the heterocyclic alkyl contains at least one heteroatom selected from nitrogen, sulfur, or any combination thereof. The heterocyclic alkyl can be selected from monocyclic or bicyclic and fused or bridged systems. The heteroatom in the heterocyclic alkyl is optionally oxidized. If one or more nitrogen atoms are present, they are optionally quaternized. The heterocyclic alkyl is partially or fully saturated. The heterocyclic alkyl is connected to the remainder of the molecule by any atom of the heterocyclic alkyl (such as any carbon or nitrogen atom of the heterocyclic alkyl) as permitted by valence. Examples of heterocyclic alkyl groups include, but are not limited to, dioxacyclopentyl, thienyl[1,3]dithiaalkyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolyl, isoxazolyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, oxazolyl, piperidinyl, piperazinyl, 4-piperidinoneyl, pyrrolyl, pyrazolyl, quininecycloyl, thiazoalkyl, tetrahydrofuranyl, trithiaalkyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxothiomorpholinyl, and 1,1-dioxothiomorpholinyl. Heterocyclic alkyl groups may optionally be substituted with one or more substituents (such as those described herein).

[0041] The term "heteroaryl" refers to a group derived from a 5- to 12-membered aromatic ring group whose ring structure contains at least one heteroatom, preferably one to four heteroatoms. In some embodiments, the heteroaryl contains at least one heteroatom selected from oxygen, nitrogen, sulfur, or any combination thereof. In some embodiments, the heteroaryl contains at least one heteroatom selected from oxygen, nitrogen, or any combination thereof. In some embodiments, the heteroaryl contains at least one heteroatom selected from oxygen, sulfur, or any combination thereof. If one or more nitrogen atoms are present, they are optionally quaternized. The heteroaryl can be linked to the remainder of the molecule via any atom of the heteroaryl (such as a carbon or nitrogen atom of the heteroaryl), provided the valence allows.

[0042] As used herein, heteroaryl rings may be selected from monocyclic or polycyclic (bicyclic and fused or bridged) ring systems, wherein at least one ring in the ring system is aromatic, i.e., according to Hückel theory, it contains a cyclic, delocalized (4n+2) π-electron system. Heteroaryl groups include aromatic monocyclic structures, preferably 5- to 6-membered rings, whose ring structure includes at least one heteroatom, preferably one to four heteroatoms, more preferably one or two heteroatoms. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, and pyrimidine. Heteroaryl groups may optionally be substituted with one or more substituents (such as those described herein). Heteroaryl groups also include polycyclic systems having two or more rings, wherein two or more atoms are common to two adjacent rings, wherein at least one ring is heteroaromatic, and the other rings may be aromatic or non-aromatic carbocyclic or heterocyclic rings.

[0043] "X-membered heterocyclic ring" refers to the number of inner ring atoms in the ring, i.e., X. For example, a 5-membered heteroaryl ring or a 5-membered aromatic heterocyclic ring has 5 inner ring atoms, such as triazole, oxazole, thiophene, etc.

[0044] "Alkoxy" refers to a group of the formula -O-alkyl that is bonded by an oxygen atom, wherein the alkyl group is an alkyl chain as defined above.

[0045] "Halogen" or "halogenated" refers to halogenated substituents, such as bromine, chlorine, fluorine, and iodine substituents.

[0046] As used herein, the term "haloalkyl" or "haloalkane" refers to an alkyl group as defined above that has been substituted with one or more halogen groups, such as trifluoromethyl, dichloromethyl, bromomethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. In some embodiments, the alkyl portion of the fluoroalkyl group may optionally be further substituted. Examples of halogen-substituted alkanes (“haloalkanes”) include halomethanes (e.g., chloromethane, bromomethane, fluoromethane, iodomethane), dihalomethanes and trihalomethanes (e.g., chloroform, tribromomethane, trifluoromethane, triiodomethane), 1-haloethane, 2-haloethane, 1,2-dihaloethane, 1-halopropane, 2-halopropane, 3-halopropane, 1,2-dihalopropane, 1,3-dihalopropane, 2,3-dihalopropane, 1,2,3-trihalopropane, and any other suitable combination of alkanes (or substituted alkanes) with halogens (e.g., Cl, Br, F, and I). When the alkyl group is substituted by more than one halogen group, each halogen can be chosen independently, for example, 1-chloro,2-fluoroethane.

[0047] The term “substituted” refers to a portion of a compound having a substituent that replaces a hydrogen atom on one or more carbon atoms or substituted heteroatoms (e.g., NH or NH2). It will be understood that “substituted” or “replaced by” includes implied limitations: such substitution is consistent with the permissible valence of the substituted atom and the substituent, and the substitution produces a stable compound, i.e., a compound that does not spontaneously undergo transformations such as rearrangement, cyclization, elimination, etc. In some embodiments, “substituted” refers to a portion having a substituent that replaces two hydrogen atoms on the same carbon atom, such as replacing two hydrogen atoms on a single carbon atom with an oxo, imino, or thio group. As used herein, the term “substituted” is contemplated to include all permissible substituents of an organic compound. In a broad sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of an organic compound. For a suitable organic compound, permissible substituents may be one or more and may be the same or different.

[0048] In some embodiments, the substituents may include any substituents described herein, such as: halogen, hydroxyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O)t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); and alkyl, alkenyl, alkynyl, aryl, aralkyl, areneyl, arynyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl and heteroarylalkyl, any one of which may optionally be substituted by: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazyl (=N-NH2), -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(Ra )2 (where t is 1 or 2); where each R a Independently selected from hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heterocycloalkylalkyl, heteroaryl, or heteroarylalkyl, wherein each R a Subject to permissible oxidation states, it may optionally be substituted with the following: alkyl, alkenyl, alkynyl, halogen, haloalkyl, haloalkenyl, haloalkynyl, oxo (=O), thio (=S), cyano (-CN), nitro (-NO2), imino (=NH), oxime (=N-OH), hydrazine (=N-NH2), -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2); and where each R b Independently selected from direct-chain or straight-chain or branched alkylene, alkenyl, or ynylene chains, and each R cIt is a straight-chain or branched alkylene, alkenylene, or ynylene chain. Those skilled in the art will understand that, where appropriate, the substituent itself can be substituted.

[0049] The term "salt" or "pharmaceutically acceptable salt" refers to a salt derived from a variety of organic and inorganic counterions well known in the art. Pharmaceutically acceptable acid addition salts can be formed from inorganic and organic acids. Pharmaceutically acceptable base addition salts can be formed from inorganic and organic bases.

[0050] The phrase “pharmaceutically acceptable” is used in this document to refer to those compounds, materials, compositions, and / or dosage forms that, to the extent of reasonable medical judgment, are suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, and in proportion to a reasonable benefit / risk ratio.

[0051] As used herein, the phrase “pharmaceuticalally acceptable excipient” or “pharmaceuticalally acceptable carrier” means a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be “acceptable” in the sense of being compatible with the other components of the formulation and harmless to the patient.

[0052] The terms “object,” “individual,” or “patient” are used interchangeably and refer to humans as well as non-human mammals (e.g., non-human primates, canines, equines, felines, suidae, bovids, ungulates, lagos, etc.). In various implementations, the object may be a human being under the care of a physician or other healthcare worker in a hospital, as an outpatient, or in another clinical setting (e.g., adult males, adult females, adolescent males, adolescent females, boys, girls). In some implementations, the object may not be under the care or prescription of a physician or other healthcare worker.

[0053] As used herein, the phrase “objects in need” refers to those who have or are at risk of developing a disease that is preventively or therapeutically treated by the compounds or salts described herein, as described below.

[0054] The terms "administer," "administered," "administers," and "administering" are defined as providing a composition to a subject via routes known in the art, including but not limited to intravenous, intra-arterial, oral, parenteral, buccal, topical, percutaneous, rectal, intramuscular, subcutaneous, intraosseous, mucosal, or intraperitoneal administration. In some embodiments, the composition may be administered orally. The terms "administered," "administered," "administers," and "administering" should be understood as indicating an intention to provide an individual in need with a compound of the present invention or a prodrug of a compound of the present invention.

[0055] As used herein, “treatment” or “treating” refers to a means of obtaining a beneficial or desired outcome (including, but not limited to, therapeutic and / or preventive benefits) with respect to a disease, condition, or medical condition. In some embodiments, treatment or treating involves administering a compound or composition disclosed herein to a subject. Therapeutic benefits may include eradicating or improving the underlying condition being treated. Moreover, therapeutic benefits may be achieved by eradicating or improving one or more physiological symptoms associated with the underlying condition, such as observing improvement in the subject, although the subject may still have the underlying condition. In some embodiments, for preventive benefits, the composition is administered to a subject at risk of developing a particular disease, or to a subject who reports one or more physiological symptoms of a disease, even if the disease may not yet be diagnosed. Treatment may include, for example, reducing or delaying one or more symptoms of a disease or condition or lessening their severity, or may include reducing the frequency with which a patient experiences symptoms of a disease, defect, condition, or adverse condition. Treatment may be used herein to refer to a method of treatment or improvement that causes a disease or condition to a certain extent, and may encompass a range of results for that purpose, including but not limited to complete prevention of the condition.

[0056] As used herein, “PF-06873600” is a competing molecule. In some embodiments, the competing molecule is derived from… The structure of (PF-06873600) represents the molecule. In some embodiments, PF-06873600 is... In some embodiments, the competing molecule is 6-(difluoromethyl)-8-((1R,2R)-2-hydroxy-2-methylcyclopentyl)-2-((1-(methylsulfonyl)piperidin-4-yl)amino)pyrido[2,3-d]pyrimidine-7(8H)-one (PF-06873600).

[0057] In some implementations, the terms “prevent” or “preventing”, when associated with a disease or condition, may refer to a compound reducing the incidence of a disease or condition in a treated sample relative to an untreated control sample, or delaying the onset or reducing the severity of one or more symptoms of a disease or condition relative to an untreated control sample.

[0058] compound In some respects, this disclosure provides compounds represented by the structure of formula (I): (I); Or its pharmaceutically acceptable salt, wherein: Ring A is selected from C 3-12 Carbon rings and 3- to 12-membered heterocycles; R 5 Selected from the electrophilic portion or its prodrug; Each R 4 Selected independently each time it appears: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11-C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i) Hydrogen, -OR14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; (ii) C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each of the ynyl groups is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14)2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 The carbon ring and 3- to 10-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14)C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: Halogen, -OR 15 -SR 15 -N(R)15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, where C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R 14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

[0059] In some embodiments, for compounds or salts of formula (I), the electrophilic moiety is a lysine-reactive electrophile. In some embodiments, the lysine-reactive electrophile is selected from reversible and irreversible lysine-reactive electrophiles.

[0060] In some embodiments, for compounds or salts of formula (I), the electrophilic moiety is selected from haloacetamides, haloalkyl ketones, haloamidines, halobenzylphosphonates, acyloxyalkyl ketones, sulfonyl ethylene oxides, epoxides, diazonyl ketones, halotriazines, acrylamides, cyanoacrylamides, vinyl sulfones, vinyl sulfonamides, acrylates, aldehydes, borate esters, halosulfonyl groups, esters, squaric acid esters, squaric acid esters, fumarate esters, carbonyl acrylates, maleimides, ketoamides, nitriles, alkenes, alkynes, ketone heterocycles, and acetylamides. In some embodiments, the electrophilic moiety is selected from haloacetamides, haloalkyl ketones, haloamidines, halobenzylphosphonates, acyloxyalkyl ketones, sulfonyl ethylene oxides, epoxides, diazonyl ketones, halotriazines, acrylamides, cyanoacrylamides, vinyl sulfones, vinyl sulfonamides, acrylates, fumarate esters, carbonyl acrylates, maleimides, ketoamides, nitriles, alkenes, alkynes, ketone heterocycles, and acetylamides. In some embodiments, the electrophilic moiety is selected from aldehydes, borate esters, and halosulfonyl groups.

[0061] In some embodiments, for compounds or salts of formula (I), the electrophilic moiety or its prodrug is an aldehyde or its prodrug. In some embodiments, R 5 The electrophilic moiety or its prodrug is an aldehyde or its prodrug. In some embodiments, R 5 The electrophilic moiety or its prodrug is an aldehyde.

[0062] In some embodiments, for compounds or salts of formula (I), the aldehyde or its prodrug is an imine. In some embodiments, R 5 The electrophilic portion or its prodrug is an imine.

[0063] In some embodiments, for compounds or salts of formula (I), the imine is formed by -C(R) 17 )=N(R 18 ) indicates; among which R 17 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 )2、-C(O)R 20 -C(O)N(R) 20 )2、-C(O)OR 20 -OC(O)R 20 -N(R) 20 )C(O)OR 20 -N(R) 20 )C(O)R 20 -S(O)R 20 -S(O)2R 20 -N(R)20 )S(O)2R 20 -S(O)2N(R) 20 )2、-NO2、=O、=S、=N(R 20 ) and -CN; R 18 Selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21)2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups; and R 20 and R 21 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbocyclic ring and the 3- to 6-membered heterocycle are each optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Halogenated alkyl groups, -NH2, -NO2, =O, and -CN.

[0064] In some implementations, for compounds or salts of formula (I), R 5 It is an imine.

[0065] In some implementations, for compounds or salts of formula (I), R 5 It is -C(R) 17 )=N(R 18 ); R 17 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 )2、-C(O)R 20 -C(O)N(R) 20 )2、-C(O)OR 20 -OC(O)R 20 -N(R) 20 )C(O)OR 20 -N(R) 20 )C(O)R 20 -S(O)R20 -S(O)2R 20 -N(R) 20 )S(O)2R 20 -S(O)2N(R) 20 )2、-NO2、=O、=S、=N(R 20 ) and -CN; R 18 Selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21-S(O)2N(R) 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups; and R 20 and R 21 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Halogenated alkyl groups, -NH2, -NO2, =O, and -CN.

[0066] In some embodiments, the compound or salt of formula (I) or (II) is represented by the structure of formula (II-A): (II-A); where rings A and R 1 R 2 R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0067] In some embodiments, the compound or salt of formula (I) or (II) is represented by the structure of formula (II-B): (II-B); where R 1 R 2 R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0068] In some embodiments, compounds or salts of formula (I) or (II) are represented by structures of formula (II-C): (II-C); where ring A is dihydroindenyl; and R 1 R 2 R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0069] In some embodiments, the compound or salt of formula (I) or (II) is represented by the structure of formula (II-D): (II-D); where R 1 and R 2 Together they form optional substituted 3- to 10-membered heterocycles, which are composed of Indicates; and rings A and R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0070] In some embodiments, compounds or salts of formula (I) or (II) are represented by structures of formula (II-E): (II-E); where rings A and R 1 R 2 R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0071] In some embodiments, compounds or salts of formula (I) or (II) are represented by structures of formula (II-F): (II-F); where rings A and R 1 R 2 R 3 R 4 L, n, R 17 and R 18 Each is as defined in equation (I) or (II).

[0072] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 17 Selected from hydrogen and C1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 )2、-C(O)R 20 -C(O)N(R) 20 )2、-C(O)OR 20 -OC(O)R 20 -N(R) 20 )C(O)OR 20 -N(R) 20 )C(O)R 20 -NO2, =O, and -CN. In some implementations, R 17 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 )2、-C(O)R 20 -C(O)N(R) 20 )2, -NO2, =O, and -CN. In some implementations, R 17 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 2. -NO2 and -CN.

[0073] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 17 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 17 Selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl groups. In some embodiments, R 17 It is hydrogen. In some implementations, R 17 It is C 1-6 Alkyl group. In some embodiments, R 17 It is C 1-3 Alkyl group. In some embodiments, R 17 It is C 1-6 Halogenated alkyl groups. In some embodiments, R 17 It is C 1-3 Halogenated alkyl groups.

[0074] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is hydrogen.

[0075] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, R 18 It is C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)OR 21 -OC(O)R 21 -S(O)2R 21 -P(=O)(OR) 21 )2、-NO2、-CN、C 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, R 18 It is C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -P(=O)(OR) 21)2、-S(O)2R 21 -NO2, -CN, C 3-6 Carbon rings and 3- to 6-membered heterocycles.

[0076] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from hydrogen; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, R 18 Selected from: hydrogen; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-NO2、=O、-CN、C 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, R 18 Selected from hydrogen; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-NO2、-CN、C 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, R 18 Selected from hydrogen; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 2. -NO2 and -CN.

[0077] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0078] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from hydrogen, .

[0079] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is C 1-6 Alkyl group, which is substituted by one or more substituents independently selected from the following: -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 ) and -CN.

[0080] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is C 1-6 Alkyl group, which is substituted by one or more substituents independently selected from the following: -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR21 -S(O)2R 21 -P(=O)(OR) 21 )2, -NO2, =O and -CN.

[0081] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is C 1-6 Alkyl group, which is substituted by one or more substituents independently selected from the following: -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -S(O)2R 21 -P(=O)(OR) 21 )2, -NO2, =O and -CN, where R 21 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0082] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from .

[0083] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is selected independently from C by one or more. 3-10 C-rings substituted with carbocyclic rings and 3- to 10-membered heterocycles 1-6 Alkyl group. In some embodiments, R 18 It is selected independently from C by one or more. 3-6 C-rings substituted with substituents of carbocyclic rings and 3- to 6-membered heterocycles 1-6 alkyl.

[0084] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 It is by one or more Cs 3-6 Carbon ring substituted C 1-6 Alkyl group. In some embodiments, R 18It is a C substituted with one or more phenyl groups. 1-6 alkyl.

[0085] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from and .

[0086] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -NO2, =O, =S, =N(R) 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-10A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -N(R) 21 )2、-C(O)R 21 -NO2, -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0087] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from C 3-7 A carbocyclic ring and 3- to 7-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-7 A carbocyclic ring and 3- to 7-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -NO2, =O, =S, =N(R) 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-7A carbocyclic ring and 3- to 7-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -N(R) 21 )2、-C(O)R 21 -NO2, -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0088] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, any one of which may optionally be substituted by one or more substituents selected from the following: halogen, -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -NO2, =O, -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, any one of which may optionally be substituted by one or more substituents selected from the following: halogen, -OR 21 -N(R) 21 )2、-NO2、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 18 Selected from C 3-6 Carbon rings and 3- to 6-membered heterocycles. In some embodiments, R 18 It is C 3-6 Carbon ring.

[0089] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 yes .

[0090] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 18 Selected from: .

[0091] In some embodiments, for compounds or salts of formula (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), Selected from: .

[0092] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), where m is 1.

[0093] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), where m is 2.

[0094] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 3 Selected from hydrogen and C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, R... 3 It is hydrogen.

[0095] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-NO2、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 4 Selected from -OH, -OMe and methyl.

[0096] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), n is selected from 1 and 2.

[0097] In some embodiments, n is 1 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F).

[0098] In some embodiments, n is 2 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F).

[0099] In some embodiments, n is 3 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F).

[0100] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), ring A is selected from C. 3-8 Carbon rings and 3- to 8-membered heterocycles. In some embodiments, ring A is C. 3-8 Carbon ring. In some embodiments, ring A is a phenyl group.

[0101] In some embodiments, for compounds or salts of formula (I), (II), (II-A), or (II-D), ring A is C. 3-12 Carbon ring. In some embodiments, ring A is C. 3-12 Saturated carbon ring. In some embodiments, ring A is C. 3-12 Unsaturated carbon ring. In some embodiments, ring A is C. 6-12 Aryl. In some embodiments, ring A is selected from C3, C4, C5, C6, C7, C8, C9, C1, C2, C3, C4, C5, C6, C7, C8, C9, C1 ...1, C2, C1, C1, C2, C1, C1, C2, C1, C1, C 10 Carbon ring, C 11 Carbon rings and C 12 Carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, ring A is selected from C. 3-4 Carbon ring, C3-5 carbon ring, C 3-6 Carbon ring, C 3-7 Carbon ring, C 3-8 Carbon ring, C 3-9 Carbon ring, C 3-10 Carbon ring, C 3-11 Carbon rings and C 3-12 Carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, ring A is selected from C. 3-8 Monocyclic carbon rings and C 4-12 Bicyclic carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, the C of ring A 3-8 Monocyclic carbon rings are selected from C 3-8Cycloalkyl and phenyl, each of which is optionally defined by R as in formula (I). 4 Replacement. In some implementations, the C of ring A 4-12 The bicyclic carbon ring is selected from C 4-12 Fused carbon rings, C 4-12 Bridging carbon rings and C 4-12 Spiral carbon rings, each of which is optionally defined by R as in equation (I). 4 replace.

[0102] In some embodiments, for compounds or salts of formula (I), (II), (II-A), or (II-D), ring A is a 3- to 12-membered heterocycle. In some embodiments, ring A is a 3- to 12-membered heterocycle containing at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, ring A is a 3- to 12-membered unsaturated heterocycle. In some embodiments, ring A is a 3- to 12-membered heteroaryl group. In some embodiments, ring A is selected from 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, and 11-membered heterocycles, each optionally represented by R as defined in formula (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 4-membered heterocycles, 3- to 5-membered heterocycles, 3- to 6-membered heterocycles, 3- to 7-membered heterocycles, 3- to 8-membered heterocycles, 3- to 9-membered heterocycles, 3- to 10-membered heterocycles, 3- to 11-membered heterocycles, and 3- to 12-membered heterocycles, each of which is optionally replaced by R as defined in formula (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 4- to 12-membered bicyclic heterocycles, each of which is optionally replaced by R as defined in formula (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles, each of which is optionally replaced by R as defined in formula (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles. In some embodiments, the 4- to 12-membered bicyclic heterocycle is selected from 4- to 12-membered fused heterocycles, 4- to 12-membered bridging heterocycles, and 4- to 12-membered spirocyclic heterocycles, each of which is optionally replaced by R as defined in formula (I). 4 replace.

[0103] In some embodiments, for compounds or salts of formula (I), (II), (II-A), or (II-D), ring A is selected from C. 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally defined by R as in formula (I). 4 Replacement. In some implementations, ring A is optionally replaced by R as defined in equation (I). 4 Replacement C3-10 Carbon ring. In some embodiments, ring A is optionally R as defined in formula (I). 4 Replacement of 3- to 10-membered heterocycles.

[0104] In some embodiments, for compounds or salts of formula (I), (II), (II-A), or (II-D), ring A is selected from C. 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, ring A is C. 6-10 Carbon ring. In some embodiments, ring A is a bicyclic C ring. 6-10 Carbon ring. In some embodiments, the bicyclic C ring of ring A. 6-10 The carbon ring is selected from C 6-10 Fused carbon rings, C 6-10 Bridging carbon rings and C 6-10 Spiral carbon ring. In some embodiments, ring A is C. 6-10 Fused carbon rings. In some embodiments, ring A is C. 6-10 Bridging carbon rings. In some implementations, ring A is C. 6-10 Spirocyclic carbocyclic ring. In some embodiments, ring A is dihydroindene. In some embodiments, ring A is dihydroindene. In some embodiments, ring A is... .

[0105] In some embodiments, for compounds or salts of formula (I) or (II), wherein Selected from .

[0106] In some implementations, for compounds or salts of formula (I) or (II), Selected from: .

[0107] In some implementations, for compounds or salts of formula (I) or (II), Selected from .

[0108] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), or (II-C), R 1 and R 2 One of them is selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group, and another one selected from: -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R)14 )2、-CN、C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, where C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2, -NO2, =O and -CN; and C 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which may optionally be substituted with: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-NO2、=O、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0109] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), or (II-C), R 1 and R 2 One of them is selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group, and another one selected from: -OR 14 -N(R) 14 2. C 1-6 Alkyl and C 2-6 alkynyl group, where C 1-6 Alkyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2 and -CN; and C 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally bonded by halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl substitution.

[0110] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), or (II-C), R 1 and R 2 One of them is selected from hydrogen, methyl, ethyl, and propyl, and the other is selected from methyl, ethyl, propyl, .

[0111] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), R 1 and R 2 Together they form a 3- to 10-membered heterocycle, which is optionally substituted by one or more independent substituents selected from the following: halogen, -OR 15 -N(R) 15 )2、-NO2、=O、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0112] In some implementations, for compounds or salts of formula (I) or (II), Selected from , and .

[0113] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Unsaturated subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Aryl groups. In some implementations, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from C3, C4, C5, C6, C7, C8, C9, C1, C2, C3, C4, C5, C6, C7, C8, C9, C1 ...1, C1, C1, C1, C1, C1, C1, C1, C1, C1 10 subcarbocyclic group and C 11 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4Any one of them is independently selected from C 3-4 Carbocyclic group, C3-5 carbocyclic group, C 3-6 subcarbocyclic group, C 3-7 subcarbocyclic group, C 3-8 subcarbocyclic group, C 3-9 subcarbocyclic group, C 3-10 subcarbocyclic group, C 3-11 subcarbocyclic group and C 3-12 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C8- 12 Bicyclic subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C 4-12 Bicyclic subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C8- 12 Bicyclic subcarbonyl cyclic group. In some embodiments, C 4-12 The subcarbonyl group is selected from C 4-12 subcarbocyclic group, C 4-12 Bridging subcarbonyl cyclogroup and C 4-12 Spirocyclic subcarbonyl group.

[0114] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered subheterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered subheterocyclic groups containing at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, L 1 L 2 L 3 or L 4Each of the groups is independently selected from 3- to 12-membered unsaturated subheterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered heteroaryl groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of them is independently selected from 3-membered heterocyclic groups, 4-membered heterocyclic groups, 5-membered heterocyclic groups, 6-membered heterocyclic groups, 7-membered heterocyclic groups, 8-membered heterocyclic groups, 9-membered heterocyclic groups, 10-membered heterocyclic groups, and 11-membered heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 4-membered heterocyclic groups, 3- to 5-membered heterocyclic groups, 3- to 6-membered heterocyclic groups, 3- to 7-membered heterocyclic groups, 3- to 8-membered heterocyclic groups, 3- to 9-membered heterocyclic groups, 3- to 10-membered heterocyclic groups, 3- to 11-membered heterocyclic groups, and 3- to 12-membered heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 4- to 12-membered bicyclic heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of them is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 8- to 12-membered bicyclic heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 8- to 12-membered bicyclic heterocyclic groups. In some embodiments, the 4- to 12-membered bicyclic heterocyclic group is selected from 4- to 12-membered fused heterocyclic groups, 4- to 12-membered bridging heterocyclic groups, and 4- to 12-membered spirocyclic heterocyclic groups.

[0115] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12)-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b)C 1-6 Alkylene, C 3-10The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0116] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b)C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12)-; and R 12 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0117] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0118] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0119] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12)N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0120] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0121] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene and C 2-6 The alkenyl group, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene and C 2-6The alkenyl group, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0122] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0123] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R12 )NC(O)N(R 12 )N(R 12 (b) C 3-10 A carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-10 A carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-6A saturated carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0124] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) - 3 to 10-membered heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) - 3 to 10-membered heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0125] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a)-N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) - 3- to 6-membered saturated heterocyclic groups and 3- to 6-membered unsaturated heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0126] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a)-N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) -5- to 6-membered heteroaryl and 6- to 10-membered bicyclic heterocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0127] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-、-S-、-N(R 12 C(O)- and -N(R) 12 )C(O)O-; and (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -N(R) 13)2 and -CN.

[0128] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L is selected from... and .

[0129] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), L is .

[0130] In some implementations, for compounds or salts of formula (I), the electrophilic moiety or its prodrug is an aldehyde or its prodrug.

[0131] In some implementations, for compounds or salts of formula (I), the aldehyde or its prodrug is an aldehyde.

[0132] In some implementations, for compounds or salts of formula (I), R 5 It is an aldehyde. In some implementations, R 5 It is -C(O)H.

[0133] In some embodiments, the compound or salt of formula (I) is represented by the structure of formula (III): (III); Or its pharmaceutically acceptable salt, wherein: Ring A is selected from C 3-12 Carbon rings and 3- to 12-membered heterocycles, Each R 4 Selected independently each time it appears: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11-N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13=O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i) Hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; (ii) C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each of the ynyl groups is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14-N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14-S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 The carbon ring and 3- to 10-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14-S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: Halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, where C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15-OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R 14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

[0134] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R)14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each independently selects from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne group. In some embodiments, R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2, -CN and C 1-6 alkyl.

[0135] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 Each is independently selected from hydrogen, -OR14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN. In some embodiments, for compounds or salts of formula (I), (II), or (III), R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN. In some implementations, R 1 and R 2 Each is independently selected from hydrogen, -OR 14 and -N(R) 14 )2; and each R 14 Independently selected from hydrogen, C 1-6 Alkyl and C1-6 Halogenated alkyl groups. In some embodiments, R 1 and R 2 Each independently selected from -OR 14 and -N(R) 14 )2; and each R 14 Independently selected from hydrogen, C 1-3 Alkyl and C 1-3 Halogenated alkyl groups. In some embodiments, R 1 and R 2 Each is independently selected from -OH, -OMe, -NMe2 and In some implementations, R 1 and R 2 Each is independently selected from hydrogen, -OH, -OMe, -NMe2, and In some implementations, R 1 and R 2 Each is independently selected from hydrogen, -OH, -OMe, -NMe2, In some implementations, R 1 and R 2 Each independently selected .

[0136] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 Each is independently selected from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14-N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R)14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

[0137] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14-N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R)14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 The alkynyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 The alkynyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)R 14 -NO2, =O, and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 The alkynyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2, -NO2, and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 Alkyne group. In some embodiments, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 alkyl, and another selected from and .

[0138] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 Each is independently selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R)14 )2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from C 3-10 A carbon ring, optionally substituted by one or more substituents independently selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 Each is independently selected from 3- to 10-membered heterocycles, optionally substituted by one or more substituents independently selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

[0139] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

[0140] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one is C. 3-10 A carbon ring, optionally substituted by one or more substituents independently selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another is optionally C 2-6 alkynyl-substituted C 3-10 Carbon ring, the C 2-6The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one is C 2-6 alkynyl-substituted C 3-10 Carbon ring, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)OR 14 -NO2, =O and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one is C 2-6 alkynyl-substituted C 3-10 Carbon ring, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN. In some implementations, R 1 and R2 One of them is selected from hydrogen and C. 1-6 Alkyl, and the other is .

[0141] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl, and another selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl, and another selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)OR 14 、N(R 14 )C(O)R 14 and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl, and another selected from -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN. In some implementations, R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from -N(R) 14 )2. In some implementation schemes, R1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from NMe2, In some implementations, R 1 and R 2 One of them is selected from NMe2, .

[0142] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 They can together form 3- to 10-membered heterocycles, which are optionally substituted by one or more independent substituents selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can together form 3- to 10-membered heterocycles, which are optionally substituted by one or more independent substituents selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2, -NO2, =O, and -CN. In some implementations, R 1 and R 2 They can together form 3- to 10-membered heterocycles, which are optionally substituted by one or more independent substituents selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2, -NO2, =O, and -CN. In some implementations, R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2 and -CN. In some implementations, R 1 and R 2 They can form 3- to 6-membered heterocycles together, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15-NO2 and -CN. In some implementations, Selected from .

[0143] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 They can together form 3- to 10-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can together form saturated 3- to 6-membered heterocycles, which are optionally converted by C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can together form saturated 3- to 6-membered heterocycles, which are optionally converted by C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2, -NO2, =O, and -CN. In some implementations, R 1 and R 2 They can be combined to form a pyrrolidinyl group, which is optionally C-shaped. 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15)2, -NO2, =O and -CN.

[0144] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), R 1 and R 2 They can together form 3- to 10-membered saturated heterocycles, which are optionally separated by one or more C atoms. 1-6 Alkyl substitution, the C 1-6 The alkyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 1-6 Alkyl substitution, the C 1-6 The alkyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2 and -CN. In some implementations Selected from .

[0145] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), or (III), Selected from .

[0146] In some respects, compounds or salts of formula (I) or (III) are represented by the structure of formula (IV): (IV); Or its pharmaceutically acceptable salt, wherein: Ring A is selected from C 3-12 Carbon rings and 3- to 12-membered heterocycles, Each R 4 Selected independently each time it appears: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11)2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i)Hydrogen; (ii) C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R)14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 The carbon ring and 3- to 10-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: Halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R 14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

[0147] In some implementations, m is 1.

[0148] In some implementations, the structure of formula (I), (III), or (IV) is represented by formula (IV-A): (IV-A), Among them, rings A and R 1 R 2 R 3 R 4 L and n are each defined as in equation (I), (III) or (IV).

[0149] In some implementations, the structure of formula (II) is represented by the structure of formula (IV-B): (IV-B).

[0150] In some implementations, the structure of formula (IV) is represented by the structure of formula (IV-B): (IV-B), Where R 1 R 2 R 3 R 4 L, ring A and n are each defined as in equation (I), (III) or (IV).

[0151] In some implementations, the structure of formula (IV) is represented by the structure of formula (IV-C): (IV-C).

[0152] In some implementations, the structure of formula (IV) is represented by the structure of formula (IV-C): (IV-C), Where R 1 R 2 R 3 R 4 L, ring A and n are each defined as in equation (I), (III) or (IV).

[0153] In some implementations, m is 0. In some implementations, m is 0 and the structure of equations (I), (III), or (IV) is represented by equation (V): (V).

[0154] In some implementations, m is 0 and the structure of equations (I), (III), or (IV) is represented by equation (V): (V), Among them, rings A and R 1 R 2 R 3 R 4 L and n are each defined as in equation (I), (III) or (IV).

[0155] In some embodiments, n is 0 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0156] In some embodiments, n is 1 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0157] In some embodiments, n is 2 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0158] In some embodiments, n is 3 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0159] In some embodiments, n is 4 for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0160] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring. In some embodiments, ring A is C. 3-12 Saturated carbon ring. In some embodiments, ring A is C. 3-12 Unsaturated carbon ring. In some embodiments, ring A is C. 6-12 Aryl. In some embodiments, ring A is selected from C3, C4, C5, C6, C7, C8, C9, C1, C2, C3, C4, C5, C6, C7, C8, C9, C1 ...1, C2, C1, C1, C2, C1, C1, C2, C1, C1, C 10 Carbon ring, C 11 Carbon rings and C 12 Carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, ring A is selected from C. 3-4 Carbon ring, C3-5 carbon ring, C 3-6 Carbon ring, C 3-7 Carbon ring, C 3-8 Carbon ring, C 3-9 Carbon ring, C 3-10 Carbon ring, C 3-11 Carbon rings and C 3-12 Carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, ring A is selected from C. 3-8 Monocyclic carbon rings and C 4-12 Bicyclic carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, the C of ring A 3-8 Monocyclic carbon rings are selected from C 3-8 Cycloalkyl and phenyl, each of which is optionally defined by R as in formula (I). 4 Replacement. In some implementations, the C of ring A 3-8 The monocyclic carbocyclic ring is phenyl. In some embodiments, the C of ring A... 4-12 The bicyclic carbon ring is selected from C 4-12 Fused carbon rings, C 4-12 Bridging carbon rings and C 4-12 Spiral carbon rings, each of which is optionally defined by R as in equation (I). 4 replace.

[0161] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 5-9 Carbon ring. In some embodiments, the C of ring A... 5-9 The carbon ring is selected from C 5-7 Monocyclic carbon rings and C 6-9 Bicyclic carbon rings, each of which is optionally defined by R as in equation (I). 4 Replacement. In some implementations, the C of ring A 5-9 The carbon ring is C 5-7 A monocyclic carbon ring, which is optionally defined by R as in formula (I). 4 Replacement. In some implementations, the C of ring A 5-9 The carbon ring is C 4-7 A monocyclic carbon ring, which is optionally defined by R as in formula (I). 4 Substitution. In some embodiments, ring A is selected from phenyl and 2,3-dihydro-1 H- Indene, each of which is optionally defined by R as in equation (I). 4 replace.

[0162] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from C. 3-10 Carbon rings and 3- to 10-membered heterocycles. In some embodiments, ring A is C. 6-10 Carbon ring. In some embodiments, ring A is a bicyclic C ring. 6-10 Carbon ring. In some embodiments, the bicyclic C ring of ring A. 6-10 The carbon ring is selected from C 6-10 Fused carbon rings, C 6-10 Bridging carbon rings and C 6-10 Spiral carbon ring. In some embodiments, ring A is C. 6-10 Bridging carbon rings. In some implementations, ring A is C. 6-10 Spiral carbon ring. In some embodiments, ring A is C. 6-10 Fused carbon ring. In some embodiments, ring A is dihydroindene. In some embodiments, ring A is dihydroindene.

[0163] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 5-9 The carbon ring has n = 0. In some embodiments, the C of ring A is... 5-9 The carbon ring is selected from C 5-7 Monocyclic carbon rings and C 6-9 A bicyclic carbon ring; and n is 0.

[0164] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 5-9 The carbon ring has n = 1. In some embodiments, the C of ring A is... 5-9 The carbon ring is selected from C 5-7 Monocyclic carbon rings and C 6-9 A bicyclic carbon ring; and n is 1.

[0165] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 5-9 The carbon ring has n = 2. In some embodiments, the C of ring A is... 5-9 The carbon ring is selected from C 5-7 Monocyclic carbon rings and C 6-9 A bicyclic carbon ring; and n is 2.

[0166] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 5-9 The carbon ring has n = 3. In some embodiments, the C of ring A is... 5-9 The carbon ring is selected from C 5-7 Monocyclic carbon rings and C 6-9 Bicyclic carbon ring; and n is 3.

[0167] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from phenyl and 2,3-dihydro-1 H- Indene; n is 0. In some embodiments, ring A is phenyl and n is 0. In some embodiments, ring A is 2,3-dihydro-1 H- Indene and n is 0. In some implementations, Selected from: , , and In some implementation schemes, Selected from: , and In some implementation schemes, yes In some implementation schemes, Selected from: , and In some implementation schemes, yes In some implementations, where yes .

[0168] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

[0169] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11)2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and A 5- to 6-membered heterocycle, optionally substituted by one or more independent substituents selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

[0170] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R)11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

[0171] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11-C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, R 4 Selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -NO2, =O, =S, =N(R) 11 ) and -CN. In some implementations, R 4 Selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -NO2 and -CN. In some implementations, R 4 Selected from ethyl, , and .

[0172] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from 3- to 10-membered heterocycles, optionally substituted by one or more independent substituents selected from: halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, R 4 Selected from 3- to 6-membered heterocycles, optionally substituted by one or more independent substituents selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, R 4 Selected from 5- to 6-membered heterocycles, optionally substituted by one or more independent substituents selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, R 4 Selected from 5- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -NO2, =O, =S, =N(R) 11 ) and -CN. In some implementations, R 4 It is a pyrazolyl group, which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -NO2, =O, =S, =N(R) 11 ) and -CN. In some implementations, R 4 Selected from .

[0173] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0174] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1; R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11-C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl. In some embodiments, n is 1; R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Haloalkyl. In some embodiments, n is 1; R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0175] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11)C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0176] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-7 Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7Carbon ring; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0177] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is phenyl; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some embodiments, ring A is phenyl; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11)S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some embodiments, ring A is phenyl; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0178] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from: In some implementation schemes, Selected from: In some implementation schemes, Selected from: In some implementation schemes, Selected from: .

[0179] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 112. -NO2 and -CN.

[0180] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11-N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0181] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-12 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11-N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0182] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-7 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-7 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0183] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is phenyl; n is 1; and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11)C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some embodiments, ring A is phenyl; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some embodiments, ring A is phenyl; n is 1; and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0184] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from , and In some implementation schemes, yes In some implementation schemes, Selected from and .

[0185] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1, and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11-N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0186] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 1, and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from halogens, C1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0187] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 1; and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 1; and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0188] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-7 Carbon ring; n is 1; and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 1; and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0189] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is phenyl; n is 1; and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some embodiments, ring A is phenyl; n is 1; and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, yes .

[0190] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 2, and for each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11)2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11-N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is independently selected from C. 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0191] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 2, and for each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R)11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R)11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, n is 2, and each R 4 Each time it appears, it is selected independently from: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, n is 2, and each R 4 Each time it appears, it is independently selected from C. 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0192] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-12 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 2; and each R 4Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11-N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-12 Carbon ring; n is 2; and each R 4 Each time it appears, it is independently selected from C. 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0193] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11)C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is selected independently from: C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11-N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, ring A is C 3-7 Carbon ring; n is 2; and each R 4 Each time it appears, it is independently selected from C. 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0194] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is phenyl; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some embodiments, ring A is phenyl; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, and -CN. In some embodiments, ring A is phenyl; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, and -CN. In some embodiments, ring A is phenyl; n is 2; and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, and -CN. In some embodiments, ring A is phenyl; n is 2; and each R 4 Each time it appears, it is selected independently from: C 1-6 Alkyl, C 2-6 alkenyl and C2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some embodiments, ring A is phenyl; n is 2; and each R 4 Each time it appears, it is independently selected from C. 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0195] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 2, and for each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and 3- to 10-membered heterocycles, optionally substituted by one or more substituents independently selected from: halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11)2, -NO2 and -CN; and 3- to 10-membered heterocycles, optionally substituted by one or more substituents independently selected from: halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and 3- to 6-membered heterocycles, optionally substituted by one or more substituents independently selected from: halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and 5- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R11 -N(R) 11 )C(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, and -CN. In some embodiments, ring A is phenyl; n is 2, and each R 4 Each time it appears, it is selected independently from: halogen, -OR 11 -N(R) 11 )2 and -CN; and 3- to 6-membered heterocycles. In some implementations, yes .

[0196] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from: In some implementation schemes, Selected from: In some implementation schemes, Selected from: .

[0197] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from: .

[0198] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 3, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11)C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 3, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0199] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 3, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 3, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0200] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 3, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R)11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 3, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R)11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0201] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 3, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 3, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11-S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0202] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 3; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 3; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R)11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0203] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-12 Carbon ring; n is 3; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-12 Carbon ring; n is 3; and R 4Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0204] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is C 3-7 Carbon ring; n is 3; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is C. 3-7 Carbon ring; n is 3; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0205] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is phenyl; n is 3; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2, -NO2, and -CN. In some embodiments, ring A is phenyl; n is 3; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0206] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), yes .

[0207] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle. In some embodiments, ring A is a 3- to 12-membered heterocycle containing at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, ring A is a 3- to 12-membered unsaturated heterocycle. In some embodiments, ring A is a 3- to 12-membered heteroaryl group. In some embodiments, ring A is selected from 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, and 11-membered heterocycles, each optionally represented by R as defined in formula (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 4-membered heterocycles, 3- to 5-membered heterocycles, 3- to 6-membered heterocycles, 3- to 7-membered heterocycles, 3- to 8-membered heterocycles, 3- to 9-membered heterocycles, 3- to 10-membered heterocycles, 3- to 11-membered heterocycles, and 3- to 12-membered heterocycles, each of which is optionally replaced by R as defined in equation (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 4- to 12-membered bicyclic heterocycles, each of which is optionally replaced by R as defined in equation (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles, each of which is optionally replaced by R as defined in equation (I). 4 Replacement. In some embodiments, ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles. In some embodiments, the 4- to 12-membered bicyclic heterocycle is selected from 4- to 12-membered fused heterocycles, 4- to 12-membered bridging heterocycles, and 4- to 12-membered spirocyclic heterocycles, each of which is optionally represented by R as defined in formula (I). 4 replace.

[0208] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle. In some embodiments, the 3- to 12-membered heterocycle is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles, each of which is optionally defined by R as in formula (I).4 Replacement. In some implementations, the 3- to 12-membered heterocycle is optionally replaced by R as defined in equation (I). 4 The 3- to 8-membered monocyclic heterocycles are replaced. In some embodiments, the 3- to 12-membered heterocycles are optionally R as defined in formula (I). 4 The substituted 8- to 12-membered bicyclic heterocycle. In some embodiments, ring A is selected from pyridinyl, isoindolinyl, dihydrobenzofuranyl, indazoleyl, benzo[d]thiazolyl, and isoquinolinyl, each of which is optionally represented by R as defined in formula (I). 4 replace.

[0209] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle, and n is 0. In some embodiments, the 3- to 12-membered heterocycle of ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles; and n is 0.

[0210] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle, and n is 1. In some embodiments, the 3- to 12-membered heterocycle of ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles; and n is 1.

[0211] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle, and n is 2. In some embodiments, the 3- to 12-membered heterocycle of ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles; and n is 2.

[0212] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle, and n is 3. In some embodiments, the 3- to 12-membered heterocycle of ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles; and n is 3.

[0213] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from pyridinyl, isoindolinyl, dihydrobenzofuranyl, indazoleyl, benzo[d]thiazolyl, and isoquinolinyl.

[0214] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from pyridinyl, isoindolinyl, dihydrobenzofuranyl, indazoleyl, benzo[d]thiazolyl, and isoquinolinyl, and n is 0. In some embodiments, n is 0.

[0215] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from .

[0216] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from pyridinyl, isoindolinyl, dihydrobenzofuranyl, indazoleyl, benzo[d]thiazolyl, and isoquinolinyl, and n is 1.

[0217] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Independently selected from halogens, -OR 11-SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN, and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 112. -NO2 and -CN.

[0218] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, n is 1, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0219] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), n is 1, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11-C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group. In some embodiments, n is 1, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0220] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11)C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is a 3- to 12-membered heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0221] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 12-membered heterocycle; n is 1; and R4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is a 3- to 12-membered heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0222] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is an 8- to 12-membered bicyclic heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11)C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN. In some implementations, ring A is an 8- to 12-membered bicyclic heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0223] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is a 3- to 8-membered monocyclic heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 112. -NO2 and -CN. In some implementations, ring A is a 3- to 8-membered monocyclic heterocycle; n is 1; and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

[0224] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from .

[0225] In some embodiments, for compounds or salts of formula (I), (II), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from In some implementation schemes, Selected from .

[0226] In some embodiments, for compounds or salts of formula (I), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), Selected from .

[0227] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Unsaturated subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-12 Aryl groups. In some implementations, L 1 L 2 L 3 or L 4 Each of the following groups is independently selected from C3 carbocyclic, C4 carbocyclic, C5 carbocyclic, C6 carbocyclic, C7 carbocyclic, C8 carbocyclic, C9 carbocyclic, C 10 subcarbocyclic group and C 11 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-4 subcarbocyclic group, C 3-5 subcarbocyclic group, C 3-6 subcarbocyclic group, C 3-7 subcarbocyclic group, C 3-8 subcarbocyclic group, C 3-9 subcarbocyclic group, C 3-10 subcarbocyclic group, C 3-11 subcarbocyclic group and C 3-12 Subcarbonyl cyclo group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C 8-12 Bicyclic subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C 4-12 Bicyclic subcarbonyl cyclic group. In some embodiments, L 1 L 2 L 3 or L 4Any one of them is independently selected from C 3-8 Monocyclic carbocyclic groups and C 8-12 Bicyclic subcarbonyl cyclic group. In some embodiments, C 4-12 The subcarbonyl group is selected from C 4-12 subcarbocyclic group, C 4-12 Bridging subcarbonyl cyclogroup and C 4-12 Spirocyclic subcarbonyl group.

[0228] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered subheterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered subheterocyclic groups containing at least one heteroatom selected from oxygen, nitrogen, and sulfur. In some embodiments, L 1 L 2 L 3 or L 4 Each of the groups is independently selected from 3- to 12-membered unsaturated subheterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of the L groups is independently selected from 3- to 12-membered heteroaryl groups. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from 3-membered heterocyclic groups, 4-membered heterocyclic groups, 5-membered heterocyclic groups, 6-membered heterocyclic groups, 7-membered heterocyclic groups, 8-membered heterocyclic groups, 9-membered heterocyclic groups, 10-membered heterocyclic groups, and 11-membered heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from 3- to 4-membered heterocyclic groups, 3- to 5-membered heterocyclic groups, 3- to 6-membered heterocyclic groups, 3- to 7-membered heterocyclic groups, 3- to 8-membered heterocyclic groups, 3- to 9-membered heterocyclic groups, 3- to 10-membered heterocyclic groups, 3- to 11-membered heterocyclic groups, and 3- to 12-membered heterocyclic groups. In some embodiments, L 1 L 2 L3 or L 4 Each of the groups is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 4- to 12-membered bicyclic heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Each of them is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 8- to 12-membered bicyclic heterocyclic groups. In some embodiments, L 1 L 2 L 3 or L 4 Any one of them is independently selected from 3- to 8-membered monocyclic heterocyclic groups and 8- to 12-membered bicyclic heterocyclic groups. In some embodiments, the 4- to 12-membered bicyclic heterocyclic group is selected from 4- to 12-membered fused heterocyclic groups, 4- to 12-membered bridging heterocyclic groups and 4- to 12-membered spirocyclic heterocyclic groups.

[0229] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b)C 1-6 Alkylene, C 2-6 imidene group, C 2-6Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0230] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 2 L 3 and L 4 Each of them does not exist, and L 1Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0231] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12)S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13=O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN. In some implementations, L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0232] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12)NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0233] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0234] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: , and In some implementations, L is selected from: and In some implementations, L is... In some implementations, L is... In some implementations, L is... .

[0235] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: , , and In some implementations, L is selected from: and In some implementations, L is... In some implementations, L is... In some implementations, L is... .

[0236] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12)-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0237] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )- and -(R 12 )NC(O)N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12)-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene and C 2-6 The alkenyl group, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN. In some implementations, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene and C 2-6 The alkenyl group, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L is selected from: In some implementations, L is selected from... and In some implementations, L is selected from... In some implementations, L is selected from... In some implementations, L is... .

[0238] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12)C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6Alkyl and C 1-6 Halogenated alkyl groups.

[0239] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 3-10 A carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R)12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-10 A carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) C 3-6 A saturated carbocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L is selected from... and .

[0240] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) - 3 to 10-membered heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) - 3 to 10-membered heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13-CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0241] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) - 3- to 6-membered saturated heterocyclic groups and 3- to 6-membered unsaturated heterocyclic groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L is selected from: .

[0242] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 3 and L 4 Each of them does not exist, and L 1and L 2 Each is independently selected from (a) and (b): (a) -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 (b) -5- to 6-membered heteroaryl and 6- to 10-membered bicyclic heterocyclic group, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L is selected from... In some implementations, L is selected from... In some implementations, L is selected from... .

[0243] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: .

[0244] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: .

[0245] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: .

[0246] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b)C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R)12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0247] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-S-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene, C 2-6 Ethyne group, C3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-、-S-、-N(R 12 C(O)- and -N(R) 12 (a)C(O)O-; and (b)C 1-6 Alkylene, C 2-6 Ethyne group, C 3-6 The carbocyclic group and the 3- to 6-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0248] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: In some implementations, L is selected from... In some implementations, L is selected from... .

[0249] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0250] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, L 1 L 2 L3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 2-6 imide and C 2-6 The ynyl group, any one of which may be optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R) 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12)S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 (b) C 1-6 Alkylene, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN. In some implementations, L is selected from: .

[0251] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is selected from: .

[0252] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is hydrogen.

[0253] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14-S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

[0254] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 -CN; and 3- to 6-membered heterocycles, optionally substituted by one or more substituents independently selected from: halogens, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN. In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and 3- to 6-membered heterocycles, optionally substituted by one or more substituents independently selected from: halogens, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and C 1-6Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from , , and .

[0255] In some embodiments, for compounds or salts of formulas (I), (II), (II-A), (III), and (II-a), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

[0256] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14)C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN. In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14) and -CN. In some implementations, R 1 Or R 2 One of them is selected from hydrogen, and R 1 Or R 2 Another one selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0257] In some implementation schemes, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 The other is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and tetrahydropyranyl, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one is selected from: In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from In some implementations, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: .

[0258] In some implementation schemes, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 The other is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, oxacyclobutyl, tetrahydropyranyl, aziroxybutyl, pyrrolidinyl, pyridyl, and phenyl, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: In some implementations, R1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: .

[0259] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

[0260] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

[0261] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

[0262] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 and R 2They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: halogens, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN. In some implementations, R 1 and R 2They can together form 3- to 6-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN. In some implementations, R 1 and R 2 They can together form 3- to 6-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN; and R 15 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, Selected from In some implementation schemes, Selected from and In some implementation schemes, Selected from In some implementation schemes, Selected from In some implementation schemes, Selected from .

[0263] In some implementation schemes, R 1 and R 2They can together form 3- to 8-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN. In some implementations, R 1 and R 2 They can together form 3- to 8-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN; and R 15 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups. In some embodiments, Selected from In some implementation schemes, Selected from In some implementation schemes, Selected from .

[0264] In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 11 R 12 R 13 R14 R 15 and R 16 Each time it appears, it is independently selected from hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-6 Carbon rings and 3- to 6-membered heterocycles; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Halogenated alkyl groups, -NH2, -NO2, =O, and -CN. In some embodiments, R... 11 R 12 R 13 R 14 R 15 and R 16 Each time it appears, it is independently selected from hydrogen and C. 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkyl-OC 1-6 Alkyl, C 1-6 Alkyl-OC 1-6 Haloalkyl, C 1-6 Alkyl-(C 3-6 carbon rings and C 1-6 Alkyl-(3- to 6-membered heterocycles), C 3-6 Carbon rings, 3- to 6-membered heterocyclic rings. In some implementations, R 11 R 12 R 13 R 14 R 15 and R 16 Each time it appears, it is independently selected from hydrogen and C. 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0265] In some respects, for compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), ring A is selected from C. 3-6 Carbon rings and 3- to 6-membered heterocycles.

[0266] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C) or (V), n is selected from 0, 1 and 2.

[0267] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 4 Selected from: Halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11-OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

[0268] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), L is derived from -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, where C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

[0269] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 3 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN.

[0270] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 It is hydrogen.

[0271] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1 or R 2 Selected from: C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14-C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0272] In some respects, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), R 1and R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R14 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

[0273] In some embodiments, the compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) are selected from the compounds in Table 1.

[0274] Table 1. Selected CDK2 modifiers. It represents the stereocenter in a single enantiomer whose absolute stereochemistry is indeterminate. In some embodiments, for compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), or (II-F), the compounds are selected from those in Table 1A.

[0275] Table 1A. Selected CDK2 prodrug compounds. This indicates a stereocenter in a single enantiomer whose absolute stereochemistry is indeterminate. While preferred embodiments of the invention have been shown and described herein, it will be apparent to those skilled in the art that such embodiments are provided by way of example only. Many variations, modifications, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein can be used to practice the invention. The scope of the invention is intended to be defined by the following claims, and covers the methods and structures within the scope of these claims and their equivalents.

[0276] Chemical entities with carbon-carbon double bonds or carbon-nitrogen double bonds can be... Z -or E - It exists in the form (either cis or trans). Furthermore, some chemical entities can exist in various tautomeric forms. Unless otherwise specified, compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) are also intended to include all Z -、 E - and tautomerism.

[0277] "Isomers" are different compounds with the same molecular formula. "Stereoisomers" are isomers that differ only in the spatial arrangement of their atoms. "Enantiomers" are a pair of stereoisomers that are not mirror images of each other. A 1:1 mixture of a pair of enantiomers is a "racemic" mixture. Where appropriate, the term "(±)" is used to designate racemic mixtures. "Diadiamers" or "diastereomers" are stereoisomers having at least two asymmetric atoms that are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog-RS system. When the compound is a pure enantiomer, the stereochemistry at each chiral carbon can be specified by R or S. Resolved compounds with unknown absolute configurations can be designated as (+) or (-) according to the direction (dextrorotatory or levorotatory) of the plane-polarized light at the wavelength of the sodium D line. Some of the compounds described herein contain one or more asymmetric centers, and thus can produce enantiomers, diastereomers, and other stereoisomers, whose asymmetric centers can be defined by absolute stereochemistry as (R)- or (S)-. These chemical entities, pharmaceutical compositions, and methods are intended to include all such possible stereoisomers, including racemic mixtures, optically pure forms, mixtures of diastereomers, and mixtures of intermediates. Optically active (R)- and (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. The optical activity of the compounds can be analyzed by any suitable method, including but not limited to chiral chromatography and optical rotation determination, and can determine the degree of dominance of one stereoisomer over another.

[0278] Compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) may, in some cases, be present in diastereomers, enantiomers, or other stereoisomers. The compounds presented herein include all diastereomers, enantiomers, and epimers, as well as racemates, mixtures of diastereomers, and other mixtures thereof, which may be prepared to some extent by those skilled in the art through routine experiments. Separation of stereoisomers may be performed by chromatography or by forming diastereomers and separating them by recrystallization or chromatography, or any combination thereof. (Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley and Sons, Inc., 1981, for which this disclosure is incorporated herein by reference). Stereoisomers can also be obtained through stereoselective synthesis. Furthermore, mixtures of two enantiomers enriched in one of them can be purified by recrystallization and / or grinding to provide other optically enriched forms of the primary enantiomer.

[0279] In some embodiments, the compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) may comprise two or more enantiomers or diastereomers of the compound, wherein a single enantiomer or diastereomer constitutes at least about 70% by weight, at least about 80% by weight, at least about 90% by weight, at least about 98% by weight, or at least about 99% by weight or more of the total weight of all stereoisomers. Methods for producing substantially pure enantiomers are well known to those skilled in the art. For example, a single stereoisomer that is substantially free of its stereoisomers (e.g., enantiomers) can be obtained by resolving racemic mixtures using methods such as forming diastereomers with optically active resolving agents (Stereochemistry of Carbon Compounds, (1962), EL Eliel, McGraw Hill; Lochmuller (1975) J. Chromatogr., 113(3): 283-302). Racemic mixtures of chiral compounds can be separated / isolated by any suitable method, including but not limited to: (1) forming ionic diastereoisomeric salts with chiral compounds and separating them by fractional crystallization or other methods; (2) forming diastereomers with chiral derivatizing agents, separating the diastereomers and converting them to pure stereoisomers; and (3) directly separating substantially pure or enriched stereoisomers under chiral conditions. Another method for separating enantiomers is to use a Diacel chiral column and elute with an organic mobile phase, such as by Chiral Technologies (www.chiraltech.com) on a charge-per-service basis.

[0280] A "tautomer" is a molecule in which a proton may translocate from one atom of the molecule to another atom of the same molecule. In some embodiments, compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) exist as tautomers. A chemical equilibrium of tautomers can exist where tautomerization is possible. The precise ratio of tautomers depends on several factors, including physical state, temperature, solvent, and pH. Some non-limiting examples of tautomeric equilibria include: .

[0281] In some embodiments, the compounds disclosed herein are used in different enriched isotopic forms, such as enriched isotopes. 2 H, 3 H, 11 C 13 C and / or 14 The content of C. In one particular embodiment, the compound is deuterated at at least one position. Such deuterated forms can be prepared by the procedures described in U.S. Patent Nos. 5,846,514 and 6,334,997. As described in U.S. Patent Nos. 5,846,514 and 6,334,997, deuteration can improve metabolic stability and / or efficacy, thus increasing the duration of drug action.

[0282] In some embodiments, some or all of the compounds disclosed herein 1 H atoms are 2 H atom substitution. Methods for synthesizing deuterium-containing compounds are known in the art and include (by way of non-limiting example only) the following synthetic methods.

[0283] Deuterium-substituted compounds are synthesized using various methods such as those described in: Dean, Dennis C.; ed. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Published in: Curr., Pharm. Des., 2000; 6(10)] 2000, p. 110; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J. Radioanal. Chem., 1981, 64(1-2), 9-32.

[0284] Deuteration starting materials are readily available and can be synthesized using the methods described herein to provide materials for the synthesis of deuterium-containing compounds. A wide range of deuterium-containing reagents and structural units are commercially available from chemical suppliers such as Aldrich Chemical Co.

[0285] Unless otherwise stated, the compounds described herein are intended to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds where hydrogen is replaced by deuterium or tritium, or carbon is replaced by... 13 C or 14 C-enriched carbon substitutions and compounds with this structure are all within the scope of this disclosure.

[0286] The compounds disclosed herein optionally contain atomic isotopes in non-natural proportions at one or more atoms constituting such compounds. For example, the compounds may contain isotopes such as, for example, deuterium (… 2 H), tritium ( 3 H), Iodine-125 ( 125 I) or carbon-14 ( 14 C) Marking. (After) 2 H, 11 C 13 C 14 C 15 C 12 N、 13 N、 15 N、 16 N、 16 O、 17 O、 14 F, 15 F, 16 F, 17 F, 18 F, 33 S, 34 S, 35 S, 36 S, 35 Cl、 37 Cl、 79 Br、 81 Br and 125 Isotope substitutions are all included. All isotopic variants of the compounds of this invention, whether or not they are radioactive, are covered within the scope of this invention.

[0287] Including in this disclosure are salts of compounds of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), particularly pharmaceutically acceptable salts. The compounds of this disclosure may have sufficiently acidic, sufficiently basic, or both functional groups to react with a variety of inorganic bases and any of inorganic and organic acids to form salts. Alternatively, inherently charged compounds (such as those having quaternary nitrogen) may form salts with suitable counterions, such as halide ions, such as bromide, chloride, or fluoride ions, especially bromide ions.

[0288] The methods and compositions of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) include the use of amorphous forms as well as crystalline forms (also known as polymorphs). The compounds described herein may be in pharmaceutically acceptable salt forms. In some embodiments, active metabolites of these compounds having the same type of activity are also included within the scope of this disclosure. Additionally, the compounds described herein may be present in unsolvable forms as well as in solvated forms formed with pharmaceutically acceptable solvents (such as water, ethanol, etc.). The solvated forms of the compounds presented herein are also considered to be disclosed herein.

[0289] Compounds of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) also include crystalline and amorphous forms of those compounds, pharmaceutically acceptable salts, and active metabolites of those compounds having the same type of activity, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, nonsolventized polymorphs (including anhydrous forms), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof.

[0290] As used herein, the term "prodrug" is intended to cover compounds that are converted into the pharmaceutical product of this disclosure under physiological conditions. In some embodiments, the term "prodrug" is intended to cover pharmaceutical compounds that are converted into compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) under physiological conditions. In some embodiments, compounds or salts of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) can be prodrugs, for example, wherein the hydroxyl group in the parent compound is present in the form of an ester or carbonate, the carboxylic acid is present in the form of an ester, or the aldehyde is present in the form of an imine. One method of preparing a prodrug comprises one or more selected moieties that are hydrolyzed under physiological conditions to release the desired molecule. In other embodiments, the prodrug is converted by the enzymatic activity of the host animal (such as specific target cells in the host animal).

[0291] In some embodiments, a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) may be a prodrug, wherein the parent compound comprises an aldehyde that may be present in the form of an imine. For example, an imine prodrug can be obtained by enzymatic or chemical hydrolysis to yield the parent aldehyde. As disclosed herein, imines are preferred prodrugs of this disclosure. In some embodiments, an imine is a preferred prodrug of a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V).

[0292] In some embodiments, compounds or salts of formulas (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V) may be prodrugs, for example, wherein the hydroxyl group in the parent compound is present in the form of an ester or carbonate, or the carboxylic acid present in the parent compound is present in the form of an ester. For example, esters or carbonates (e.g., esters or carbonates of alcohols or carboxylic acids and esters of phosphonic acids) are preferred prodrugs of this disclosure.

[0293] Prodrugs are often useful because, in some cases, they can be more readily administered than the parent drug. For example, they may have bioavailability through oral administration, while the parent drug may not. Prodrugs can help improve the cellular permeability of a compound relative to the parent drug. Prodrugs may also have superior solubility in pharmaceutical compositions compared to the parent drug. Prodrugs can be engineered as reversible drug derivatives to act as modifiers that enhance drug transport to target tissues or increase drug retention within cells.

[0294] In some embodiments, the prodrug can be converted into the parent compound under intracellular conditions (e.g., by enzymatic or chemical means). In some embodiments, the parent compound contains an acidic moiety, such as that produced by the hydrolysis of the prodrug, which can be charged under intracellular conditions. In certain embodiments, the prodrug is converted into the parent compound once it crosses the cell membrane and enters the cell. In some embodiments, the parent compound has reduced cell membrane permeability relative to the prodrug, such as reduced lipophilicity and increased hydrophilicity.

[0295] In some implementations, the prodrug design increases the drug's lipophilicity. In some implementations, the prodrug design increases effective water solubility. See, for example, Fedorak et al. Am. J. Physiol. , 269:G210-218(1995); McLoed et al., Gastroenterol , 106:405-413 (1994); Hochhaus et al., Biomed. Chrome ., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics , 37,87 (1987); J. Larsen et al., Int. J. Pharmaceutics , 47, 103 (1988); Sinkula et al., J. Pharm. Sci. , 64:181-210 (1975); T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems , the ACS Symposium Series, Volume 14; and Edward B. Roche, Bioreversible Carriers in Drug Design (American Pharmaceutical Association and Pergamon Press, 1987, all of which are incorporated herein by reference). According to another embodiment, this disclosure provides a method for preparing the above-described compounds. The compounds can be synthesized using conventional techniques. Advantageously, these compounds can be readily synthesized from readily available starting materials.

[0296] Useful synthetic chemical transformations and methods for synthesizing the compounds described herein are known in the art, including, for example, those of R. Larock. Comprehensive Organic Transformations (1989); TW Greene and PGMUTS, Protective Groups in Organic Synthesis , 2nd edition (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis (1994); edited by L. Paquette, Encyclopedia of Reagents for Organic Synthesis Those described in (1995).

[0297] pharmaceutical preparations In some aspects, this disclosure provides pharmaceutical compositions comprising a compound or salt of formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C) or (V), and at least one pharmaceutically acceptable excipient.

[0298] Pharmaceutical compositions may be formulated usi...

Claims

1. A compound represented by the structure of formula (I): (I)； Or its pharmaceutically acceptable salt, wherein: Ring A is selected from C 3-12 carbocyclic and 3- to 12-membered heterocyclic; R 5 selected from an electrophilic moiety or a prodrug thereof; Each R 4 Selected independently each time it appears: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2, =O, =S, =N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R[[ID=​​​​​​​​​ (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i) hydrogen, -OR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , N(R 14 )C(O)R 14 , -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2 and -CN; (ii) C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each of the ynyl groups is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 The carbon ring and 3- to 10-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: halogen, -OR 15 , -SR 15 , -N(R 15 )2, -C(O)R 15 , -C(O)N(R 15 )2, -N(R 15 )C(O)R 15 , -C(O)OR 15 , -OC(O)R 15 , -N(R 15 )C(O)OR 15 , -OC(O)N(R 15 )2, -N(R 15 )C(O)N(R 15 )2, -S(O)R 15 , -S(O)2R 15 , -N(R 15 )S(O)2R 15 , -S(O)2N(R 15 )2, -NO2, =O, =S, =N(R 15 ) and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R 14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

2. The compound or salt according to claim 1, wherein the electrophilic portion is a lysine reactive electrophile.

3. The compound or salt according to claim 2, wherein the lysine reactive electrophile is selected from reversible lysine reactive electrophiles and irreversible lysine reactive electrophiles.

4. The compound or salt according to claim 1, wherein the electrophilic portion is selected from haloacetamides, haloalkyl ketones, haloamidines, halobenzylphosphonates, acyloxyalkyl ketones, sulfonyl ethylene oxides, epoxides, diazoalkyl ketones, halotriazines, acrylamides, cyanoacrylamides, vinyl sulfones, vinyl sulfonamides, acrylates, aldehydes, borates, halosulfonyl groups, esters, squaric acid esters, squaric acid esters, fumarates, carbonyl acrylates, maleimides, ketoamides, nitriles, alkenes, alkynes, ketone heterocycles, and acetyleneamides.

5. The compound or salt according to claim 1, wherein the electrophilic portion is selected from haloacetamides, haloalkyl ketones, haloamidines, halobenzylphosphonates, acyloxyalkyl ketones, sulfonyl ethylene oxides, epoxides, diazoalkyl ketones, halotriazines, acrylamides, cyanoacrylamides, vinyl sulfones, vinyl sulfonamides, acrylates, fumarates, carbonyl acrylates, maleimides, ketoamides, nitriles, alkenes, alkynes, ketone heterocycles, and acetyleneamides.

6. The compound or salt according to claim 3, wherein the electrophilic moiety is selected from aldehydes, borate esters and halosulfonyl groups.

7. The compound or salt according to claim 1, wherein the electrophilic moiety or its prodrug is an aldehyde or its prodrug.

8. The compound or salt according to claim 7, wherein the aldehyde or its prodrug is an imine.

9. The compound or salt according to claim 1, wherein R 5 It is an imine.

10. The compound or salt according to claim 1, wherein R 5 It is -C(R) 17 )=N(R 18 ); R 17 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 20 -SR 20 -N(R) 20 )2、-C(O)R 20 -C(O)N(R) 20 )2、-C(O)OR 20 -OC(O)R 20 -N(R) 20 )C(O)OR 20 -N(R) 20 )C(O)R 20 -S(O)R 20 -S(O)2R 20 -N(R) 20 )S(O)2R 20 -S(O)2N(R) 20 )2、-NO2、=O、=S、=N(R 20 ) and -CN; R 18 Selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups; and R 20 and R 21 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Carbon rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Halogenated alkyl groups, -NH2, -NO2, =O, and -CN.

11. The compound or salt according to any one of claims 1 to 10, wherein the structure of formula (I) is represented by the structure of formula (II): (II)。 12. The compound or salt according to claim 10 or 11, wherein R 17 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

13. The compound or salt according to claim 12, wherein R 17 It is hydrogen.

14. The compound or salt according to any one of claims 10 to 13, wherein R 18 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

15. The compound or salt according to claim 14, wherein R 18 Selected from hydrogen, , , , , , and .

16. The compound or salt according to any one of claims 10 to 13, wherein R 18 It is C 1-6 Alkyl group, which is substituted by one or more substituents independently selected from the following: -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-P(=O)(OR 21 )2、-NO2、=O、=S、=N(R 21 ) and -CN.

17. The compound or salt according to claim 16, wherein R 18 It is C 1-6 Alkyl group, which is substituted by one or more substituents independently selected from the following: -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -S(O)2R 21 -P(=O)(OR) 21 )2, -NO2, =O and -CN, where R 21 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

18. The compound or salt according to claim 17, wherein R 18 Selected from , , , , and .

19. The compound or salt according to any one of claims 10 to 13, wherein R 18 It is selected independently from C by one or more. 3-10 C-rings substituted with carbocyclic rings and 3- to 10-membered heterocycles 1-6 alkyl.

20. The compound or salt according to claim 19, wherein R 18 It is by one or more Cs 3-6 Carbon ring substituted C 1-6 alkyl.

21. The compound or salt according to claim 20, wherein R 18 Selected from and .

22. The compound or salt according to any one of claims 10 to 13, wherein R 18 Selected from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 21 -SR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -OC(O)R 21 -N(R) 21 )C(O)OR 21 -N(R) 21 )C(O)R 21 -S(O)R 21 -S(O)2R 21 -N(R) 21 )S(O)2R 21 -S(O)2N(R) 21 )2、-NO2、=O、=S、=N(R 21 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

23. The compound or salt according to claim 22, wherein R 18 Selected from C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, any one of which may optionally be substituted by one or more substituents selected from the following: halogen, -OR 21 -N(R) 21 )2、-C(O)R 21 -C(O)N(R) 21 )2、-C(O)OR 21 -NO2, =O, -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

24. The compound or salt according to claim 23, wherein R 18 yes .

25. The compound or salt according to claim 10 or 11, wherein... Selected from: 。 26. The compound or salt according to any one of claims 10 to 25, wherein m is 1.

27. The compound or salt according to any one of claims 10 to 26, wherein R 3 Selected from hydrogen and C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

28. The compound or salt according to claim 27, wherein R 3 It is hydrogen.

29. The compound or salt according to any one of claims 10 to 28, wherein R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-NO2、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

30. The compound or salt according to claim 29, wherein R 4 Selected from -OH, -OMe and methyl.

31. The compound or salt according to any one of claims 10 to 30, wherein n is selected from 1 and 2.

32. The compound or salt according to any one of claims 10 to 31, wherein ring A is selected from C. 3-10 Carbon rings and heterocyclic rings ranging from 3 to 10 members.

33. The compound or salt according to claim 32, wherein ring A is C 6-10 Carbon ring.

34. The compound or salt according to claim 33, wherein ring A is a bicyclic ring C. 6-10 Carbon ring.

35. The compound or salt according to claim 34, wherein the bicyclic C of ring A 6-10 The carbon ring is selected from C 6-10 Fused carbon rings, C 6-10 Bridging carbon rings and C 6-10 Spiral carbon ring.

36. The compound or salt according to claim 35, wherein ring A is C 6-10 Fused carbon rings.

37. The compound or salt according to claim 36, wherein ring A is dihydroindenyl.

38. The compound or salt according to any one of claims 7 to 11, wherein Selected from 。 39. The compound or salt according to any one of claims 10 to 31, wherein ring A is selected from C. 3-8 Carbon rings and 3- to 8-membered heterocycles.

40. The compound or salt according to claim 39, wherein ring A is C 3-8 Carbon ring.

41. The compound or salt according to claim 40, wherein ring A is phenyl.

42. The compound or salt according to any one of claims 10 to 41, wherein R 1 and R 2 One of them is selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group, and another one selected from: -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2, -CN and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2, -NO2, =O and -CN; and C 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally converted by halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-NO2、=O、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl substitution.

43. The compound or salt according to claim 42, wherein R 1 and R 2 One of them is selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl group, and another one selected from: -OR 14 -N(R) 14 2. C 1-6 Alkyl and C 2-6 alkynyl group, wherein the C 1-6 Alkyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2 and -CN; and C 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally bonded by halogens, C 1-6 Alkyl and C 1-6 Halogenated alkyl substitution.

44. The compound or salt according to claim 43, wherein R 1 and R 2 One of them is selected from hydrogen, methyl, ethyl, and propyl, and the other is selected from methyl, ethyl, propyl, , , , , and .

45. The compound or salt according to any one of claims 10 to 41, wherein R 1 and R 2 Together they form a 3- to 10-membered heterocycle, which is optionally substituted by one or more independent substituents selected from the following: halogen, -OR 15 -N(R) 15 )2、-NO2、=O、-CN、C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

46. ​​The compound or salt according to claim 45, wherein... Selected from , and .

47. The compound or salt according to any one of claims 10-46, wherein L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-、-S-、-N(R 12 C(O)- and -N(R) 12 )C(O)O-; and (b) C 1-6 Alkylene, optionally substituted by one or more substituents independently selected from: halogen, -OR 13 -N(R) 13 )2 and -CN.

48. The compound or salt according to claim 47, wherein L is selected from... and .

49. The compound or salt according to claim 47, wherein L is .

50. The compound or salt according to claim 11, wherein the compound of formula (II) is selected from the compounds in Table 1A.

51. The compound or salt according to claim 7, wherein the aldehyde or its prodrug is an aldehyde.

52. The compound or salt according to claim 1, wherein R 5 It is an aldehyde.

53. The compound or salt according to claim 1, wherein R 5 It is -C(O)H.

54. The compound or salt according to any one of claims 1 to 3, 4 to 7 and 50 to 53, wherein the structure of formula (I) is represented by the structure of formula (III): (III)。 55. The compound or salt according to claim 54, wherein R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 、N(R 14 )C(O)R 14 -S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2 and -CN.

56. The compound or salt according to claim 55, wherein R 1 and R 2 Each is independently selected from hydrogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN.

57. The compound or salt according to claim 56, wherein R 1 and R 2 Each is independently selected from hydrogen, -OR 14 and -N(R) 14 )2; and each R 14 Independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

58. The compound or salt according to claim 57, wherein R 1 and R 2 Each is independently selected from -OH, -OMe, -NMe2 and .

59. The compound or salt according to claim 57, wherein R 1 and R 2 Each is independently selected from hydrogen, -OH, -OMe, -NMe2, , , , , and .

60. The compound or salt according to claim 54, wherein R 1 and R 2 Each is independently selected from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

61. The compound or salt according to claim 54, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

62. The compound or salt according to claim 61, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 The alkynyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

63. The compound or salt according to claim 62, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 2-6 The alkynyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 2. -NO2 and -CN.

64. The compound or salt according to claim 63, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 alkyl, and another selected from and .

65. The compound or salt according to claim 54, wherein R 1 and R 2 Each is independently selected from C 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally composed of one or more independently selected from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Substitution of the alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

66. The compound or salt according to claim 54, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from C4. 3-10 Carbon rings and 3- to 10-membered heterocycles, each of which is optionally composed of one or more independently selected from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Substitution of the alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Each alkynyl group may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

67. The compound or salt according to claim 66, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another is optionally C 2-6 alkynyl-substituted C 3-10 carbon ring, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

68. The compound or salt according to claim 67, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one is C 2-6 alkynyl-substituted C 3-10 carbon ring, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2 and -CN.

69. The compound or salt according to claim 68, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl, and the other is .

70. The compound or salt according to claim 54, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl, and another selected from -OR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2 and -CN.

71. The compound or salt according to claim 70, wherein R 1 and R 2 One of them is selected from hydrogen and C. 1-6 Alkyl group, and another one selected from -N(R) 14 )2.

72. The compound or salt according to claim 71, wherein -N(R) 14 )2 is selected from -NMe2, , , , and .

73. The compound according to claim 54, wherein R 1 and R 2 They can together form 3- to 10-membered heterocycles, which are optionally composed of one or more independent rings selected from C. 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Substituent substitution of the alkynyl group, wherein the C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN.

74. The compound or salt according to claim 73, wherein R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN.

75. The compound or salt according to claim 74, wherein R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 2-6 Alkyne substitution, the C 2-6 The alkynyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2 and -CN.

76. The compound or salt according to claim 75, wherein... yes .

77. The compound according to claim 54, wherein R 1 and R 2 They can together form 3- to 10-membered heterocycles, which are optionally composed of one or more independent rings selected from C. 1-6 Alkyl substituents, wherein the C 1-6 The alkyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN.

78. The compound according to claim 77, wherein R 1 and R 2 They can form 3- to 10-membered heterocycles, which are optionally C 1-6 Alkyl substitution, the C 1-6 The alkyl group is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2 and -CN.

79. The compound or salt according to claim 73, wherein... Selected from , , and .

80. The compound or salt according to claim 54, wherein... Selected from , , , and .

81. The compound according to any one of claims 54 to 77, wherein R 3 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN.

82. The compound according to claim 81, wherein R 3 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

83. The compound according to claim 82, wherein R 3 Selected from hydrogen.

84. The compound or salt according to any one of claims 54 to 83, wherein ring A is selected from C. 3-10 Carbon rings and heterocyclic rings ranging from 3 to 10 members.

85. The compound or salt according to claim 84, wherein ring A is C 6-10 Carbon ring.

86. The compound or salt according to claim 85, wherein ring A is a bicyclic ring C. 6-10 Carbon ring.

87. The compound or salt according to claim 86, wherein the bicyclic C of ring A 6-10 The carbon ring is selected from C 6-10 Fused carbon rings, C 6-10 Bridging carbon rings and C 6-10 Spiral carbon ring.

88. The compound or salt according to claim 87, wherein ring A is C 6-10 Fused carbon rings.

89. The compound or salt according to claim 88, wherein ring A is dihydroindenyl.

90. The compound or salt according to any one of claims 54 to 89, wherein yes .

91. The compound or salt according to claim 85, wherein ring A is phenyl.

92. The compound or salt according to any one of claims 54 to 85 or 91, wherein yes .

93. The compound or salt according to any one of claims 54 to 92, wherein L is selected from... and .

94. The compound or salt according to claim 1 or claim 54, wherein the structure of formula (I) or formula (III) is represented by the structure of formula (IV): (IV); Or its pharmaceutically acceptable salt; wherein: Ring A is selected from C 3-12 Carbon rings and 3- to 12-membered heterocycles, Each R 4 Selected independently each time it appears: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2, =O, =S, =N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; L by -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; Where L 2 L 3 and L 4 Each of the two optional locations does not exist; Where L 1 L 2 L 3 and L 4 No more than two of them are selected from (a), and the two selected are not adjacent; R 1 and R 2 Each is independently selected from (i), (ii), and (iii): (i) Hydrogen; (ii) C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ), -CN; and C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and (iii) C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; or R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: halogen, -OR 15 , -SR 15 , -N(R 15 )2, -C(O)R 15 , -C(O)N(R 15 )2, -N(R 15 )C(O)R 15 , -C(O)OR 15 , -OC(O)R 15 , -N(R 15 )C(O)OR 15 , -OC(O)N(R 15 )2, -N(R 15 )C(O)N(R 15 )2, -S(O)R 15 , -S(O)2R 15 , -N(R 15 )S(O)2R 15 , -S(O)2N(R 15 )2, -NO2, =O, =S, =N(R 15 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN; R 3 Selected from: Hydrogen, halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN; R 11 R 12 R 13 R 14 R 15 and R 16 Each occurrence is independently selected from: hydrogen; C 1-6 Alkyl groups, optionally composed of one or more elements independently selected from halogens, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH2, -NO2, =O, -CN, C 3-10 Substituents of carbocyclic rings and 3- to 10-membered heterocycles, wherein each C 3-10 The carbocyclic ring and the 3- to 10-membered heterocyclic ring are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; and C 3-6 The carbon ring and 3- to 6-membered heterocycles are optionally substituted by one or more substituents independently selected from the following: halogen, -OH, -OC. 1-6 Alkyl, -OC 1-6 Haloalkyl groups, -NH2, -NO2, =O, and -CN; n is selected from 0, 1, 2, 3, and 4; and m is selected from 0 and 1.

95. The compound or salt according to claim 94, wherein m is 1, and the structure of formula (IV) is represented by formula (IV-A): (IV-A)。 96. The compound or salt according to claim 94 or claim 95, wherein the structure of formula (IV) is represented by the structure of formula (IV-B): (IV-B).

97. The compound or salt according to claim 94 or claim 95, wherein the structure of formula (IV) is represented by the structure of formula (IV-C): (IV-C).

98. The compound or salt according to any one of claims 94 to 97, wherein ring A is C 3-12 Carbon ring.

99. The compound or salt according to claim 98, wherein ring A is C 5-9 Carbon ring.

100. The compound or salt according to claim 99, wherein ring A is selected from phenyl and 2,3-dihydro-1 H- Indene.

101. The compound or salt according to claim 100, wherein ring A is selected from phenyl and 2,3-dihydro-1 H- Indene; n is 0.

102. The compound or salt according to claim 101, wherein... Selected from: , , and .

103. The compound or salt according to claim 101, wherein... Selected from: , and .

104. The compound or salt according to any one of claims 98 to 100, wherein n is 1, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

105. The compound or salt according to claim 104, wherein n is 1; R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)N(R 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

106. The compound or salt according to claim 105, wherein... Selected from: 。 107. The compound or salt according to claim 105, wherein... Selected from: 。 108. The compound or salt according to any one of claims 98 to 100, wherein n is 1, and R 4 Selected independently from C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

109. The compound or salt according to claim 108, wherein n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

110. The compound or salt according to claim 109, wherein n is 1, and R 4 Selected independently from C 1-6 Alkyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

111. The compound or salt according to claim 110, wherein... Selected from: , and .

112. The compound or salt according to any one of claims 98 to 100, wherein n is 1, and R 4 Selected independently from C 3-10 A carbocyclic ring and 3- to 10-membered heterocycles, each optionally substituted by one or more substituents independently selected from the following: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

113. The compound or salt according to claim 112, wherein n is 1, and R 4 Independently selected from 3- to 6-membered heteroaryl groups, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

114. The compound or salt according to claim 113, wherein... yes .

115. The compound or salt according to any one of claims 98 to 100, wherein n is 2, and each R 4 Selected independently each time it appears: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2 and -CN; and C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

116. The compound or salt according to claim 115, wherein n is 2, and each R 4 Selected independently each time it appears: Halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

117. The compound or salt according to claim 116, wherein... Selected from: 。 118. The compound or salt according to claim 116, wherein... Selected from: 。 119. The compound or salt according to any one of claims 98 to 100, wherein n is 2, and each R 4 Selected independently each time it appears: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2 and -CN; and A 3- to 10-membered heterocyclic ring, optionally substituted by one or more independent substituents selected from: halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

120. The compound or salt according to any one of claims 119, wherein n is 2, and each R 4 Selected independently each time it appears: Halogen, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN; and A 3- to 6-membered heterocycle, optionally substituted by one or more independent substituents selected from: halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 2. -NO2 and -CN.

121. The compound or salt according to claim 120, wherein... yes .

122. The compound or salt according to any one of claims 98 to 100, wherein n is 3, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

123. The compound or salt according to claim 122, wherein... yes .

124. The compound or salt according to any one of claims 94 to 97, wherein ring A is a 3- to 12-membered heterocycle.

125. The compound or salt according to claim 124, wherein ring A is selected from 3- to 8-membered monocyclic heterocycles and 8- to 12-membered bicyclic heterocycles.

126. The compound or salt according to claim 125, wherein ring A is selected from pyridyl, isoindoline, dihydrobenzofuranyl, indazole, benzo[d]thiazolyl, isoquinolinyl, and isoquinolinyl.

127. The compound or salt according to claim 126, wherein n is 0.

128. The compound or salt according to claim 127, wherein... Selected from , , and .

129. The compound or salt according to any one of claims 124 to 126, wherein n is 1, and R 4 Independently selected from halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

130. The compound or salt according to claim 129, wherein n is 1, and R 4 Independently selected from halogens, -OR 11 -N(R) 11 )2、-C(O)R 11 -N(R) 11 )C(O)OR 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2, -NO2 and -CN; and R 11 Selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

131. The compound or salt according to claim 130, wherein... Selected from 。 132. The compound or salt according to any one of claims 94 to 97, wherein Selected from: 。 133. The compound or salt according to any one of claims 94 to 97, wherein Selected from 。 134. The compound or salt according to any one of claims 94 to 133, wherein L 2 L 3 and L 4 Each of them does not exist, and L 1 Selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

135. The compound or salt according to claim 134, wherein L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )C(O)C(O)N(R 12 )-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )-、-S(O)(NR 12 )N(R 12 )-、-N(R 12 )N(R 12 )-、-(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

136. The compound or salt according to claim 135, wherein L 1 Selected from -N(R) 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

137. The compound or salt according to claim 135, wherein L 1 Selected from -N(R) 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)C(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )-; and R 12 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

138. The compound or salt according to claim 136, wherein L is selected from: , and .

139. The compound or salt according to claim 137, wherein L is selected from: , , and .

140. The compound or salt according to any one of claims 94 to 133, wherein L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 ); and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

141. The compound or salt according to claim 139, wherein L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O-、-N(R 12 )S(O)2-、-N(R 12 )S(O)2N(R 12 )- and -(R 12 )NC(O)N(R 12 )-;as well as (b) C 1-6 Alkylene, C 2-6 imidene group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally selected by one or more independently chosen from halogens, -OR 13 Substitution with -CN.

142. The compound or salt according to claim 141, wherein L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-、-N(R 12 C(O)- and -N(R) 12 )C(O)O-; and (b) C 1-6 Alkylene and C 2-6 Alkenyl groups, each of which is optionally selected independently from one or more halogens, -OR 13 Substitution with -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

143. The compound or salt according to claim 142, wherein L is selected from: 。 144. The compound or salt according to claim 141, wherein L 3 and L 4 Each of them does not exist, and L 1 and L 2 Each is independently selected from (a) and (b): (a) -N(R 12 )-、-N(R 12 )C(O)-、-N(R 12 )C(O)O- and -(R 12 )NC(O)N(R 12 )-;as well as (b) C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally selected by one or more independently chosen from halogens, -OR 13 Substitution with -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

145. The compound or salt according to claim 144, wherein L is selected from... 。 146. The compound or salt according to claim 142 or claim 145, wherein L is selected from: 。 147. The compound or salt according to any one of claims 94 to 133, wherein L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

148. The compound or salt according to claim 147, wherein L 4 It does not exist, and L 1 L 2 and L 3 Each is independently selected from (a) and (b): (a) -O-、-N(R 12 )-、-S-、-N(R 12 C(O)- and -N(R) 12 )C(O)O-; and (b) C 1-6 Alkylene, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -CN,C 1-6 Alkyl; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

149. The compound or salt according to claim 148, wherein L is selected from: 。 150. The compound or salt according to any one of claims 94 to 133, wherein L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN; and R 13 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

151. The compound or salt according to claim 150, wherein L is selected from: 、 。 152. The compound or salt according to any one of claims 94 to 133, wherein L is selected from: 。 153. The compound or salt according to any one of claims 94 to 133, wherein L is selected from: 。 154. The compound or salt according to any one of claims 94 to 153, wherein R 1 or R 2 One of them is hydrogen.

155. The compound or salt according to any one of claims 94 to 153, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ) and -CN; and C 3-6 A carbocyclic ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

156. The compound or salt according to claim 155, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

157. The compound or salt according to claim 156, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from .

158. The compound or salt according to claim 156, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from 。 159. The compound or salt according to claim 155, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ) and -CN; and A 3- to 6-membered heterocycle, optionally substituted by one or more independent substituents selected from: halogens, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

160. The compound or salt according to claim 159, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from , , and .

161. The compound or salt according to claim 155, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from 。 162. The compound or salt according to any one of claims 94 to 152, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 3-6 The carbon ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 , -SR 14 , -N(R 14 )2, -C(O)R 14 , -C(O)N(R 14 )2, -N(R 14 )C(O)R 14 , -C(O)OR 14 , -OC(O)R 14 , -N(R 14 )C(O)OR 14 , -OC(O)N(R 14 )2, -N(R 14 )C(O)N(R 14 )2, -S(O)R 14 , -S(O)2R 14 , -N(R 14 )S(O)2R 14 , -S(O)2N(R 14 )2, -NO2, =O, =S, =N(R 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN.

163. The compound or salt according to claim 162, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another one selected from C 3-6 The carbon ring and 3- to 6-membered heterocycles, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

164. The compound or salt according to claim 163, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 The other is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and tetrahydropyranyl, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

165. The compound or salt according to claim 163, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 The other is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, oxetyl, tetrahydropyranyl, aziryl, pyrrolidinyl, pyridyl, and phenyl, each of which is optionally substituted by one or more substituents independently selected from the following: Halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -N(R) 14 )2、-C(O)R 14 -NO2, =O, =S, =N(R) 14 ) and -CN; and R 14 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

166. The compound or salt according to claim 164, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 167. The compound or salt according to claim 164, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 168. The compound or salt according to claim 164, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 169. The compound or salt according to claim 164, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 170. The compound or salt according to claim 165, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 171. The compound or salt according to claim 165, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 172. The compound or salt according to any one of claims 94 to 152, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 173. The compound or salt according to any one of claims 94 to 152, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 174. The compound or salt according to any one of claims 94 to 152, wherein R 1 or R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: 。 175. The compound or salt according to any one of claims 94 to 153, wherein R 1 and R 2 They can together form 3- to 10-membered heterocycles, which may optionally be substituted by one or more independent substituents selected from the following: Halogen, -OR 15 , -SR 15 , -N(R 15 )2, -C(O)R 15 , -C(O)N(R 15 )2, -N(R 15 )C(O)R 15 , -C(O)OR 15 , -OC(O)R 15 , -N(R 15 )C(O)OR 15 , -OC(O)N(R 15 )2, -N(R 15 )C(O)N(R 15 )2, -S(O)R 15 , -S(O)2R 15 , -N(R 15 )S(O)2R 15 , -S(O)2N(R 15 )2, -NO2, =O, =S, =N(R 15 ) and -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -SR 15 -N(R) 15 )2、-C(O)R 15 -C(O)N(R) 15 )2、-N(R 15 )C(O)R 15 -C(O)OR 15 -OC(O)R 15 -N(R) 15 )C(O)OR 15 -OC(O)N(R) 15 )2、-N(R 15 )C(O)N(R 15 )2、-S(O)R 15 -S(O)2R 15 -N(R) 15 )S(O)2R 15 -S(O)2N(R) 15 )2、-NO2、=O、=S、=N(R 15 ) and -CN.

176. The compound or salt according to claim 175, wherein R 1 and R 2 They can together form 3- to 6-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN; and R 15 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

177. The compound or salt according to claim 175, wherein R 1 and R 2 They can together form 3- to 8-membered saturated heterocycles, which are optionally substituted by one or more independent substituents selected from the following: halogens, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ), -CN; and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 15 -N(R) 15 )2、-C(O)R 15 -NO2, =O, =S, =N(R) 15 ) and -CN; and R 15 Each time it appears, it is independently selected from hydrogen, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

178. The compound or salt according to claim 176, wherein... Selected from , , and .

179. The compound or salt according to claim 176, wherein... Selected from: 。 180. The compound or salt according to claim 177, wherein... Selected from: 。 181. The compound or salt according to claim 94, wherein ring A is selected from C. 3-6 Carbon rings and 3- to 6-membered heterocycles.

182. The compound or salt according to claim 181, wherein n is selected from 0, 1 and 2.

183. The compound or salt according to claim 181 or claim 182, wherein R 4 Selected from: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2, =O, =S, =N(R 11 ) and -CN; C 1-6 Alkyl, C 2-6 alkenyl and C 2-6 Alkyne groups, each of which is optionally substituted by one or more substituents independently selected from: halogen, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

184. The compound or salt according to claim 183, wherein R 4 Selected from ethyl, , and .

185. The compound or salt according to claim 181 or 182, wherein R 4 Selected from: halogen, -OR 11 , -SR 11 , -N(R 11 )2, -C(O)R 11 , -C(O)N(R 11 )2, -N(R 11 )C(O)R 11 , -C(O)OR 11 , -OC(O)R 11 , -N(R 11 )C(O)OR 11 , -OC(O)N(R 11 )2, -N(R 11 )C(O)N(R 11 )2, -S(O)R 11 , -S(O)2R 11 , -N(R 11 )S(O)2R 11 , -S(O)2N(R 11 )2, -NO2, =O, =S, =N(R 11 ) and -CN; A 5- to 6-membered heterocycle, optionally substituted by one or more substituents independently selected from: halogens, -OR 11 -SR 11 -N(R) 11 )2、-C(O)R 11 -C(O)N(R) 11 )2、-N(R 11 )C(O)R 11 -C(O)OR 11 -OC(O)R 11 -N(R) 11 )C(O)OR 11 -OC(O)N(R) 11 )2、-N(R 11 )C(O)N(R 11 )2、-S(O)R 11 -S(O)2R 11 -N(R) 11 )S(O)2R 11 -S(O)2N(R) 11 )2、-NO2、=O、=S、=N(R 11 ) and -CN.

186. The compound or salt according to claim 185, wherein R 4 yes .

187. The compound or salt according to any one of claims 181 to 186, wherein L is derived from -L 1 -L 2 -L 3 -L 4 - indicates that L 1 L 2 L 3 and L 4 Each is independently selected from (a) and (b): (a) -O-, -N(R 12 )-, -S-, -S(O)-, -S(O)2-, -S(O)(NR 12 )-, -N(R 12 )C(O)-, -N(R 12 )C(O)O-, -N(R 12 )C(O)C(O)N(R 12 )-, -N(R 12 )S(O)2-, -N(R 12 )S(O)2N(R 12 )-, -S(O)(NR 12 )N(R 12 )-, -N(R 12 )N(R 12 )-, -(R 12 )NC(O)N(R 12 )- and -(R 12 )NC(O)N(R 12 )N(R 12 )-; and (b) C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 The carbocyclic group and the 3- to 10-membered heterocyclic group, any one of which may optionally be substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, -CN, C 1-6 Alkyl and C 3-6 Carbon ring, wherein the C 1-6 Alkyl and C 3-6 Each carbon ring is optionally substituted by one or more substituents independently selected from the following: halogen, -OR 13 -SR 13 =O, =S, and -CN.

188. The compound or salt according to any one of claims 181 to 187, wherein R 3 Selected from hydrogen and C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 16 -SR 16 -N(R) 16 )2、-C(O)R 16 -C(O)N(R) 16 )2、-C(O)OR 16 -NO2 and -CN.

189. The compound or salt according to any one of claims 181 to 188, wherein R 1 or R 2 It is hydrogen.

190. The compound or salt according to any one of claims 181 to 188, wherein R 1 or R 2 Selected from: C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

191. The compound or salt according to any one of claims 181 to 188, wherein R 1 and R 2 One of them is selected from hydrogen, and R 1 or R 2 Another selection from: C 1-6 Alkyl group, optionally substituted by one or more substituents independently selected from: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 ) and -CN; and C 3-6 A carbon ring, optionally substituted by one or more substituents independently selected from the following: halogen, -OR 14 -SR 14 -N(R) 14 )2、-C(O)R 14 -C(O)N(R) 14 )2、-N(R 14 )C(O)R 14 -C(O)OR 14 -OC(O)R 14 -N(R) 14 )C(O)OR 14 -OC(O)N(R) 14 )2、-N(R 14 )C(O)N(R 14 )2、-S(O)R 14 -S(O)2R 14 -N(R) 14 )S(O)2R 14 -S(O)2N(R) 14 )2、-NO2、=O、=S、=N(R 14 -CN, C 1-6 Alkyl and C 1-6 Halogenated alkyl groups.

192. The compound or salt according to claim 94, wherein m is 0, and the structure of formula (IV) is represented by formula (IV-D): (IV-D).

193. The compound or salt according to claim 54 or claim 94, wherein the compound of formula (III) or formula (IV) is selected from the compounds in Table 1.

194. A pharmaceutical composition comprising the compound or salt of any one of claims 1 to 193, and a pharmaceutically acceptable excipient.

195. A method for regulating CDK2, comprising administering to a subject in need a compound or salt of any one of claims 1 to 193, or a pharmaceutical composition of claim 194.

196. A method of inhibiting CDK2, comprising administering to a subject in need a compound or salt of any one of claims 1 to 193, or a pharmaceutical composition of claim 194.

197. A method of treating a disease or condition mediated by CDK2, comprising administering to a subject in need a compound or salt of any one of claims 1 to 193, or a pharmaceutical composition of claim 194.

198. A method for inhibiting cell proliferation, comprising administering to a subject in need a compound or salt of any one of claims 1 to 193, or a pharmaceutical composition of claim 194.

199. The method of claim 198, wherein the cell proliferation is cancer cell proliferation.

200. The method according to claim 199, wherein the proliferation of cancer cells is selected from breast cancer proliferation, ovarian cancer proliferation, bladder cancer proliferation, uterine cancer proliferation, prostate cancer proliferation, lung cancer proliferation, esophageal cancer proliferation, head and neck cancer proliferation, colorectal cancer proliferation, kidney cancer proliferation, liver cancer proliferation, pancreatic cancer proliferation, gastric cancer proliferation, and thyroid cancer proliferation.

201. A method of treating cancer, comprising administering to a subject in need a compound or salt of any one of claims 1 to 193, or a pharmaceutical composition of claim 194.

202. The method of claim 201, wherein the cancer is selected from breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer, and thyroid cancer.

203. The method according to any one of claims 195 to 202, wherein the application is selective for CDK2 relative to a CDK selected from CDK1, CDK4 and CDK6.

204. A CDK2 protein covalently bound to a compound, wherein the compound is covalently bound to a lysine residue of the CDK2 protein.

205. The CDK2 protein according to claim 204, wherein the compound is an exogenous CDK2 regulator.

206. The CDK2 protein according to claim 204, wherein the compound is an exogenous CDK2 inhibitor.

207. The CDK2 protein of claim 206, wherein the exogenous CDK2 inhibitor is the compound or salt of claim 1, or the pharmaceutical composition of claim 194.

208. The CDK2 protein according to any one of claims 204 to 207, wherein the lysine residue is selected from K6, K9, K20, K24, K33, K34, K56, K65, K88, K89, K105, K129, K142, K178, K237, K242, K250, K273, K278 and K291.

209. The CDK2 protein according to claim 208, wherein the lysine residue is selected from K20, K33, K89, K129, K178 and K278.

210. The CDK2 protein of claim 208, wherein the lysine residue is K89.

211. The CDK2 protein according to any one of claims 204 to 210, wherein the CDK2 protein is in vivo.

212. The CDK2 protein of claim 211, wherein the CDK2 protein is an in vivo engineered CDK2 protein, wherein the in vivo engineered CDK2 protein is produced by contacting the CDK2 protein with the compound in vivo.

213. The CDK2 protein according to claim 212, wherein the in vivo engineered CDK2 protein is a human in vivo engineered CDK2 protein.

214. The CDK2 protein according to any one of claims 204 to 213, wherein the covalent bond between the compound and the lysine residue is a reversible covalent bond.

215. The CDK2 protein according to claim 214, wherein the reversible covalent bond in the in vivo CDK2 protein is a carbon-nitrogen double bond.

216. The CDK2 protein of claim 215, wherein the carbon-nitrogen double bond is formed by a reversible reaction between the amine functional group of K89 and the aldehyde functional group on the compound.

217. The CDK2 protein according to claim 216, wherein the aldehyde functional group is an aromatic aldehyde.

218. An in vivo engineered CDK2 protein comprising a non-naturally occurring reversible covalent modification at a lysine residue, said reversible covalent modification being generated by an in vivo nucleophilic reaction between an exogenous aromatic aldehyde and a lysine residue of CDK2, wherein the exogenous aromatic aldehyde undergoes nucleophilic addition with an amine functional group on the lysine residue, and a carbon-nitrogen double bond is formed between the exogenous aromatic aldehyde and the amine functional group on the lysine residue.

219. The in vivo engineered CDK2 protein according to claim 218, wherein the lysine residue is selected from K6, K9, K20, K24, K33, K34, K56, K65, K88, K89, K105, K129, K142, K178, K237, K242, K250, K273, K278 and K291.

220. The in vivo engineered CDK2 protein according to claim 219, wherein the lysine residue is selected from K20, K33, K89, K129, K178 and K278.

221. The in vivo engineered CDK2 protein according to claim 219, wherein the lysine is K89.

222. The in vivo engineered CDK2 protein according to any one of claims 218 to 221, wherein the in vivo engineered CDK2 protein is a human in vivo engineered CDK2 protein.

223. A method for covalently modifying a CDK2 protein, comprising contacting the CDK2 protein with an exogenous CDK2 modulator, wherein the exogenous CDK2 modulator comprises a reversibly electrophilic moiety, thereby forming a reversible covalent CDK2 adduct.

224. The method of claim 223, wherein the contact is an external contact.

225. The method of claim 223, wherein the contact is an in vivo contact.

226. The method according to any one of claims 223 to 225, wherein the exogenous CDK2 modulator is an exogenous CDK2 inhibitor.

227. The method according to any one of claims 223 to 226, wherein the reversible electrophilic portion is an aromatic aldehyde.

228. A method for attenuating CDK2 activity, comprising contacting a CDK2 protein with an exogenous CDK2 inhibitor, wherein the exogenous CDK2 inhibitor comprises a reversibly electrophilic moiety.

229. The method of claim 228, wherein the contact is an external contact.

230. The method of claim 229, wherein after the contact, CDK2 activity is reduced by 50% or more relative to a control in which the exogenous CDK2 inhibitor is absent.

231. The method of claim 230, wherein after the contact, CDK2 activity is reduced by 70% or more relative to a control in which the exogenous CDK2 inhibitor is absent.

232. The method according to any one of claims 223 to 231, wherein the exogenous CDK2 inhibitor is the compound or salt of claim 1, or the pharmaceutical composition of claim 194.

Images